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Summary  
Despite the enormous replication potential of the human liver, there are currently no culture 
systems available that sustain hepatocyte replication and/or function in vitro. We have shown 
previously that single mouse Lgr5+ liver stem cells can be expanded as epithelial organoids in 
vitro and can be differentiated into functional hepatocytes in vitro and in vivo. We now 
describe conditions allowing long-term expansion of adult bile duct-derived bi-potent 
progenitor cells from human liver. The expanded cells are highly stable at the chromosome 
and structural level, while single base changes occur at very low rates. The cells can readily 
be converted into functional hepatocytes in vitro and upon transplantation in vivo. Organoids 
from α1-antitrypsin deficiency and Alagille Syndrome patients mirror the in vivo pathology. 
Clonal long-term expansion of primary adult liver stem cells opens up experimental avenues 
for disease modeling, toxicology studies, regenerative medicine and gene therapy. 
 
Highlights  
 Establishment of a long-term human liver organoid culture 
 Human liver stem cells retain genetic stability after long-term expansion 
 Liver organoid cultures differentiate to functional hepatocytes in vitro and in vivo 
 Organoids derived from patients with genetic disorders model liver disease in vitro 
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Introduction 
 
The liver is the largest organ in the human body, and is mainly composed of two different 
epithelial cell types, hepatocytes and ductal cells. It synthesizes essential serum proteins and 
plays a key role in the homeostasis of metabolism and in the detoxification of a wide variety 
of endogenous and exogenous molecules. All these functions are performed primarily by 
hepatocytes (Duncan et al., 2009). Despite the considerable replication capacity of 
hepatocytes in vivo (Michalopoulos, 2013), liver cells have essentially resisted long-term 
expansion in culture (Casciano, 2000; Mitaka, 1998). Indeed, a recent study describes a 
human liver hepatocyte culture system with preservation of hepatocyte function, yet overall 
expansion cell numbers was 10-fold and the culture could only be expanded over a period of 
~ 1 week (Shan et al., 2013). 
 
Stem cells (ES, iPS or adult tissue-resident stem cells) represent an attractive alternative cell 
source, because of their unlimited self-renew capacity. Both, hES and hiPS cells have been 
differentiated towards hepatocyte-like cells in a stepwise manner using defined factors. 
However, recent reports have unveiled that genetic and epigenetic aberrations occur during 
the derivation and reprogramming process (Liang and Zhang, 2013; Pera, 2011). These range 
from chromosomal abnormalities (Laurent et al., 2011), sub-chromosomal changes such as 
“de novo” copy number variations (CNVs) (Hussein et al., 2011) and point mutations in 
protein coding regions (Gore et al., 2011). Such changes may complicate their use for 
regenerative medicine purposes (Bayart and Cohen-Haguenauer, 2013).  
 
We have recently described a novel culture system that allows the long-term expansion (>1 
year) of single mouse adult intestine (Sato et al., 2009), stomach (Barker et al., 2010), liver 
(Huch et al., 2013b) and pancreas (Huch et al., 2013a) stem cells. Lgr5, the receptor for the 
Wnt agonists R-spondins (Carmon et al., 2011; de Lau et al., 2011), marks adult stem cells in 
these mouse tissues (Barker et al., 2010; Barker et al., 2007; Huch et al., 2013a; Huch et al., 
2013b). Furthermore, these cultures remain committed to their tissue-of-origin, that is, 
intestinal stem cells only generate organoids harboring intestinal lineages. We have recently 
adapted the technology to allow culturing of human intestinal stem cells (Jung et al., 2011; 
Sato et al., 2011), and shown that patient-derived intestinal organoids recapitulate the 
pathology of hereditary intestinal diseases (Bigorgne et al., 2014; Dekkers et al., 2013; 
Wiegerinck et al., 2014). Here, we pursue the establishment of an organoid culture system for 
human liver. 
 
Results 
 
Optimization of human liver stem cell culture 
We recently described a defined mouse liver culture medium that allows long-term expansion 
of mouse liver stem cells in culture in the absence of a mesenchymal niche (Huch et al., 
2013b). This cocktail (ERFHNic, or ‘mouse liver medium’) supported the growth of human 
liver cells only for 2-3 weeks, after which the cultures quickly deteriorated (Figure 1A-B and 
Figure S1A, top panel). We then sought to define a culture system that would allow the long-
term expansion of human liver cells in vitro. Gene expression profiles of human liver cultures 
that were maintained for 2 weeks in ‘mouse liver medium’ revealed that the Tgf-β signaling 
pathway was highly activated in the cultures. Tgf-β target genes such as CTGF, PLAT, 
TIMP1 and TIMP2 (Dooley and ten Dijke, 2012; Verrecchia et al., 2001) were highly 
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expressed while Tgf-β sequesters (LTBP2 and LTBP3) and Smad4 inhibitors (SMURF1 and 
SMURF2) (Massague et al., 2005) were virtually absent (Figure S1B). It is known that Tgf-β 
signaling results in growth arrest (Massague et al., 2000) and epithelial-to-mesenchymal 
transition in vivo (Xu et al., 2009). Specific inhibition of Tgf-β receptors Alk4/5/7 by the 
small molecule inhibitor A8301, which does not target the BMP-GDF Alk receptors 
(Alk1/2/3/6)(Schmierer and Hill, 2007), resulted in downregulation of the Tgf-β target genes 
CTGF, TIMP2, PLAT (Figure S1C) and in a significant increase in colony forming efficiency 
(Figure 1D). More importantly, upon A8301 addition, the cells expanded for longer period of 
time in culture (~6-7 weeks, 6-7 splits) (Figure 1B). However, after that period, the cultures 
again deteriorated (Figure 1B and Figure 1C, left panel). We noticed that the expression of 
the progenitor/stem cell marker LGR5 decreased over time, while differentiation markers such 
as Albumin (ALB) or CYP3A4 were upregulated (not shown), indicating that our conditions 
were promoting differentiation at the cost of self-renewal and long-term maintenance of liver 
progenitor cells in culture.  
 
In addition to A8301, we then tested candidate compounds to induce liver cell proliferation 
and/or Lgr5 expression in culture (see Table S1). Liver progenitors have been identified in the 
ductal tree, both during homeostasis (Furuyama et al., 2011) and after damage (Dorrell et al., 
2011; Huch et al., 2013b; Shin et al., 2011). Mouse liver organoids containing Lgr5+ cells are 
largely composed of bile duct-derived bi-potent progenitor/stem cells. Similarly, human liver 
organoid cultures maintained in mouse medium supplemented with TGF inhibitor were 
mainly composed of ductal-like cells. Because administration of Forskolin (FSK), a cAMP 
pathway agonist, results in enhanced proliferation of biliary duct cells in vivo (Francis et al., 
2004), we asked whether cAMP would support the human liver cultures.  
In the presence of FSK, LGR5 and the ductal marker KRT19 were upregulated, while the 
expression of the hepatocyte differentiation markers ALB and CYP3A4 decreased (Figure 
S1D). Colony forming efficiency was essentially unchanged, when compared to A8301 
treatment alone (Figure 1D), but upon FSK treatment, the cultures expanded for many months 
in culture (> 6 months) maintaining a weekly split ratio of 1:4-1:6 (Figure 1B). The cells grew 
out into organoids that formed budding domains also observed in mouse liver cultures (Figure 
1C, right panel). Similar results were observed when other cAMP agonists were used (8-
BrcAMP, Cholera toxin or NKH477) (Figure S1E). Consistent with this, removal of cAMP 
agonists (e.g. FSK) resulted in rapid loss of proliferation and deterioration of the cultures 
(Figure S1F-G). Similarly, removal of the Wnt agonist R-spo or blockage of Wnt secretion by 
porcupine inhibition (IWP-2) resulted in rapid deterioration and loss of the cultures (Figure 
S1F-H). This effect was rescued by exogenous addition of Wnt in the medium (Figure S1H), 
again indicating that active Wnt signaling is essential for the long-term expansion of the 
cultures. 
 
To generalize our findings across multiple donors, we obtained 12 additional healthy human 
donor liver biopsies and cultured them in our improved human liver medium. Table S2 
summarizes the data. Under our improved conditions (ERFHNic + Tgfbi + FSK), all 12 
human liver-derived cultures grew exponentially, with a consisting doubling time of ~60h 
independent of the age of the culture (2 weeks or 3 months) (Figure 1E/F). EdU incorporation 
confirmed that the cells maintained their proliferative state in vitro (Figure 1G) 3 months after 
the initiation of culture. Of note, cultures grown under these culture conditions could be 
readily frozen and thawed (data not shown). Overall, these results indicated that the 
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combination of Wnt signaling and cAMP activation, combined with Tgf-β inhibition, is 
essential to sustain long-term expansion of human liver progenitors in vitro.  
 
Human liver organoid cultures initiate from ductal cells  
To assess the cell-of-origin of our cultures, we FACS-purified hepatocytes and duct cells 
from 3 independent human hepatocyte isolations instead of liver biopsies. Hepatocyte 
isolations by collagenase perfusion yield high numbers of fresh, viable and functional human 
hepatocytes that are used for hepatocyte transplantation infusions (Gramignoli et al., 2012) 
(Figure S2A). We employed EpCAM to differentially sort hepatocytes (EpCAM-) from ductal 
cells (EpCAM+, bile duct and canal of herring ductal /progenitor cells, Figure 1H and Figure 
S2B and S2C) (Schmelzer et al., 2007; Yoon et al., 2011). While hepatocytes did not yield 
organoids in our cell culture conditions (colony formation efficiency 0%), ductal (EpCAM+) 
cells developed into long-term, self-renewing organoid structures with a striking efficiency of 
28.4 ± 3.2% (Figure 1H and Figure S2D-E). When crude hepatocyte preparations (not 
differentially sorted) were directly cultured, cells grew into organoid structures with an 
efficiency that correlated directly with the amount of residual EpCAM+ cells in the crude 
preparation (Figure S2F-G). Therefore, we concluded that in our culture system ductal cells 
and not hepatocytes revert to a bi-potential progenitor state. 
 
Human liver cultures established from single human liver cells are genetically stable 
Genetic stability is a concern for the future application of cells that have undergone derivation 
and expansion in culture (Lund et al., 2012). Adult stem cells may have evolved to minimize 
the risk of accumulating somatic mutations (Cairns, 1975). Indeed, karyotyping of clonal 
human liver organoids cultured for 3 months revealed that the cells maintain normal 
chromosome numbers over time (Figure 3A and Figure S4A). The ability to repeatedly 
generate clonal cultures from single liver stem cells allowed us to isolate sufficient DNA for 
WGS analysis and subsequent characterization of the mutational load present in the cultured 
cells after several months of in vitro expansion (Figure 2A).  
From two donors, we obtained biopsy samples, which we dissociated and cultured in bulk for 
7 days. Subsequently, we isolated single cells by flow cytometry and established 2 
independent clonal lines for each of the two livers (cultures A and B). After 3 months of 
expanding these cultures, a second cloning step was performed. The combined procedure 
allowed us to determine all the genomic variation that had accumulated in a single cell during 
life, derivation, and 3 months of culturing (Figure 2B). 
 
We observed 720 – 1424 base substitutions per cultures of which only a small part was 
introduced during the 3 months culture, which is equivalent to 13 weekly passages (63 – 139; 
Figure 2C). The majority of the base substitutions were therefore incorporated during life or 
introduced during organoid derivation. Interestingly, we observe twice as many base 
substitutions in both cultures derived from donor 1 compared to the cultures derived from 
donor 2 (Figure 2C). This is most probably the result of the high age of donor 1 (74 years) 
compared to donor 2 (30 years), suggesting that the majority of the somatic base substitutions 
we observed were acquired during life. 
How do these numbers compare to published data? It has been reported that iPS cells contain 
1,058 – 1,808 de novo base substitutions per line (determined at passage numbers between 15 
and 25) when compared to their parental somatic cells (Cheng et al., 2012). Of note, these 
numbers do not include the variation acquired in vivo in the parental somatic cells, which we 
did determine here for the clonal liver organoid cultures. We therefore conclude that liver 
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organoid cultures accumulate in the order of 10-fold fewer base substitutions during in vitro 
expansion compared to iPS cells. Of the total number of base substitutions only few were 
located in protein coding DNA (7 – 9 base substitutions per culture; Figure 2D). With the 
exception of one synonymous mutation in culture A from donor 2 (Table S3), all mutations 
were already present in the early passage clonal cultures, indicating that they were 
incorporated during life or organoid derivation and not during 3 months-expansion. None of 
the mutated genes occurs in COSMIC databases (Table S3). In iPS cells, it has been reported 
that an average of 6 base substitutions per line affect protein coding DNA (Cheng et al., 2012; 
Gore et al., 2011) which were reported to be enriched for genes mutated or being drivers in 
cancers (Gore et al., 2011).  
Next, we checked for evidence of chromosomal aberrations in the WGS data of the different 
liver organoid cultures. In line with our karyotyping analysis, we did not observe any 
chromosomal aberration (Figure 3B). We observed 2 copy number variants (CNVs), 
heterozygous gains, in one of the liver organoid cultures (Figures 3C). In the other cultures, 
we did not detect any CNV (Figure 3D and Figure S4). Moreover, these 2 CNVs were already 
present in the early passage cultures and therefore did not result from long-term culturing, 
suggesting they were either acquired in vivo or during organoid derivation. ES cell cultures 
routinely show abnormal karyotypes (Baker et al., 2007) and iPS cells have been reported to 
harbor considerable amounts of somatic CNVs (Hussein et al., 2011; Laurent et al., 2011) 
(Martins-Taylor et al., 2011; Mayshar et al., 2010) (Abyzov et al., 2012), complicating their 
clinical use. 
 
Human liver cultures express markers of ductal and hepatocyte lineages 
We next examined the lineage potential of our liver stem cell cultures. The stem cell markers 
PROM1 and LGR5, as well as ductal (SOX9, OC2) and hepatocyte markers (HNF4a) were 
readily expressed (Figure 4A and Figure S5A-B). Histologically, liver organoids displayed a 
duct-like phenotype characterized by two types of epithelia: 1) a single-layered epithelium 
formed by polarized cells with basal nuclei, expressing cytokeratin epithelial markers (KRT19 
and KRT7), and 2) a pseudo-stratified epithelium with non-polarized E-Cadherin+ HNF4a+ 
and some KRT7+ cells (Figure 4B-D). SOX9 (Figure 4E) and EPHB2 (Figure 4F) were 
detectable in almost all the cells within an organoid while LGR5 was detectable within the 
EPHB2+ population (Figure 4F).  
 
Differentiation into functional hepatocytes in vitro and upon transplantation 
Similar to what we had observed with the mouse liver organoid cultures under expansion 
conditions, the human counterparts failed to express markers of mature hepatocytes, such as 
Albumin or CYP3A4 (Figure 4A and Figure 5C, EM bars). Therefore, we defined a human 
differentiation medium (DM) by combining our acquired knowledge on mouse hepatocyte 
differentiation with known hepatocyte differentiation-promoting compounds (Table S1). 
Removal of the growth stimuli R-spo and FSK directly resulted in the up-regulation of 
Albumin and CYP3A4 gene expression (Figure S5C). To this medium, we then added the 
Notch inhibitor DAPT (Huch et al., 2013b), FGF19 (Wu et al., 2011) and dexamethasone 
(Rashid et al., 2010) (Figure S5D). BMP7 is known to accelerate liver regeneration and 
hepatocyte proliferation in vivo (Sugimoto et al., 2007). When testing compounds to improve 
our culture conditions, we noticed that BMP7 slightly facilitated the expression of hepatocyte 
markers ALB and CYP3A4, without compromising the proliferation ability of the culture 
itself (data not shown). Therefore, 5-7 days prior to the start of differentiation, we 
supplemented the expansion medium (EM) with 25ng/ml BMP7, which was then maintained 
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during the differentiation step (Figure 5A). Using this combination of growth factors (BMP7, 
FGF19, HGF and EGF), small molecule inhibitors (DAPT and A8301) and Dexamethasone, 
the cells acquired pronounced hepatocyte morphologies, including polygonal cell shapes, as 
made visible by ZO-1 staining (Figure 5B). We subsequently examined the level of maturity 
of the differentiated cells by using gene expression profiling, immunofluorescence and 
various biochemical assays. 
 
Gene expression profiles proved that the differentiated cultures expressed high levels of 
hepatocyte markers (Figure 5D). Hepatocyte specific genes such as ALB, several cytochrome 
enzymes, Apolipoproteins (APOB) and several complement factors (C3) were readily 
expressed upon differentiation in all 4 donors analyzed (Figure 5D). We confirmed these 
results by qPCR and RT-PCR analysis for selected genes (ALB, several cytochromes, and 
TAT) (Figure 5C and Figure S5E) and found that the differentiated cultures express levels of 
cytochrome CYP3A4 expression similar to that of human liver tissue. A 100-1000x fold 
increase in Albumin expression was also detected on the DM-treated cultures, although the 
expression levels were still 1000x lower when compared to freshly isolated human liver 
material. Immunofluorescence visualized cells with high levels of ALB and MRP4 within the 
organoids (Figure 5B). Similar results were obtained with cultures derived from EpCAM+ 
sorted cells (Figure S5F-G) 
We next assessed the ability of the hepatocyte cells to retain hepatocyte function in vitro. 
Immunohistochemistry analysis indicated that the cells could accumulate glycogen (Figure 
6A) and take up LDL (Figure 6B). Biochemical analyses demonstrated that the differentiated 
cells secreted high levels of Albumin into the medium (Figure 6C). Cytochrome family 
members, such as Cyp3a4, are expressed exclusively in mature hepatocytes. They play an 
important detoxifying function for exogenous molecules in the liver (Casciano, 2000). Upon 
differentiation, the cultures exhibited similar p450-3A4 activity as fresh isolated hepatocytes 
(Figure 6D, compare to Figure S2A). We also observed that the differentiated cultures 
hydroxylated midazolam, another indication of functional CYP3A3/4/5 activity (Wandel et 
al., 1994), and glucuronidated hydroxy-midazolam, thereby showing evidence of both phase I 
and II detoxifying reactions (Figure 6E). We then assessed the ability of the cultured cells to 
synthetize bile acids, a hallmark of hepatocyte function. Upon differentiation, bile acid salts 
were readily secreted into the medium (Figure 6F). Finally, the cultures also exhibited the 
ability to detoxify ammonia at similar levels to HepaRG cells (Figure 6G). In all cases, the 
expanded human liver organoids showed stronger hepatocyte functions when compared to the 
standard/reference cell line HepG2 cells (Figure 6).  
 
To test the ability of the cultures to engraft in damaged tissue and to fully differentiate into 
functional hepatocytes in vivo, we treated Balb/c nude mice with CCl4-retrorsine to induce 
acute liver damage. As shown by others, this treatment is permissive for the engraftment of 
hepatocytes (Guo et al., 2002; Schmelzer et al., 2007). Using human-specific antibodies 
(Figure S6A), we initially detected Krt19 positive, ductal-like cells at 2h and d2 after 
transplantation, distributed throughout the liver parenchyma (Figure S6B). At later time 
points, we observe Albumin+, Krt19- human cells as singlets or doublets or, more rarely, in 
larger hepatocyte foci in the mouse liver (Figure 6H and Figure S6C). This agreed with the 
non-chronic nature of our damage model, which provides no stimulus for expansion of the 
transplant after the initial engraftment. We detected human Albumin and human alpha-1-
antitrypsin in the circulation of recipient mice within 7-14 days (Figure 6I and Suppl Figure 
6D/E), at a level that remained stable for more than 60 days in 5/6 mice and for more than 
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120 days in 2/5 animals. While transplantation of primary human hepatocytes initially yielded 
higher levels of human Albumin in mouse circulation (Figure 6I), the levels approximated 
those of transplanted organoids within a month. Presence of human albumin and human 
alpha-1-antitrypsin in mouse serum proved, together with Albumin and Krt19 stainings, that 
transplanted cells differentiated into human hepatocytes in vivo.  
 
Organoids from human patients model disease pathogenesis in vitro 
Encouraged by the establishment of a culture medium that allows the long-term expansion of 
genetically stable liver cells, we explored whether our culture system would be suitable for 
disease modeling. A1AT deficiency is an inherited disorder that predisposes to chronic 
obstructive pulmonary disease and chronic liver disease (Stoller and Aboussouan, 2005). 
Alpha-1 antitrypsin is a protease produced in the liver, which functions to protect the lung 
against proteolytic damage from neutrophil elastase. The most frequent mutation causing a 
severe phenotype is the Z allele, which involves a substitution of glutamic acid with lysine at 
position 342 (Glu342Lys) in the SERPINA1 gene, which causes accumulation of misfolded 
α1-antitrypsin in the endoplasmic reticulum of hepatocytes. The ZZ mutant phenotype is 
characterized by a ~80% reduction of the protein in plasma, which subsequently causes lung 
emphysema (Stoller and Aboussouan, 2005). 
   
We obtained human liver biopsies from 3 patients diagnosed with A1AT deficiency who were 
undergoing liver transplantation (Table S2). Biopsies were divided into samples for 
histological characterization, RNA isolation, DNA isolation and for expansion in culture. We 
confirmed that all 3 patients carried the homozygous Z allele (PiZZ), by Sanger sequencing of 
the SERPINA1 locus (Figure S7A). The isolated cells rapidly grew into 3-D structures 
generating organoids that closely resembled the organoids derived from healthy biopsies 
(Figure 7A) and were grown for >4 months in culture at a 1:5 split ratio/week, similar as the 
cultures derived from healthy/donor biopsies. 
We then confirmed the ability of the A1AT-D derived cultures (PiZZ cultures) to differentiate 
into functional hepatocytes in vitro. Gene expression analysis demonstrated that the cells 
differentiated normally. When submitted to hierarchical clustering analysis, differentiated 
organoids derived from A1AT-deficient patients clustered together with differentiated 
organoids derived from healthy donor biopsies (Figure S7B). Of note, functional tests 
revealed that the differentiated cells from A1AT patients secrete high levels of Albumin and 
take up LDL similar to healthy donor-derived organoid cultures (Figure 7B-D).  
  
We then analyzed the ability of the cultured cells to mimic the pathology of the disease in 
vitro.  Functional, healthy hepatocytes secrete A1AT protein into the bloodstream to inhibit 
neutrophil elastase mainly in the lungs (Figure 7E). In A1AT-deficiency, the molecular 
pathogenesis of the liver disease relates to the aggregation of the protein within the 
endoplasmic reticulum of hepatocytes (Lawless et al., 2008). A1AT-Protein aggregates were 
readily observed within the cells of the differentiated organoids derived from the A1AT-D 
patient (Figure 7H), similar to what was found in the original biopsy (Figure 7G), while these 
aggregates were essentially absent from the organoids derived from healthy donor-material 
(Figure 7F). A1AT ELISA confirmed reduced secretion of the protease inhibitor from PiZZ 
organoids (Figure 7I), which mimics the reduced A1AT serum levels in patients (Table S2 
indicates the A1AT secretion per patient). Likewise, supernatants from differentiated ZZ 
mutant organoids showed a strongly reduced ability to block elastase activity (Figure 7J). 
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Advanced stages of A1AT deficiency are characterized by liver injury and cirrhosis due to 
combined effects of uncontrolled protease activity and apoptotic loss of functional 
hepatocytes (Fairbanks and Tavill, 2008). Protein misfolding and resulting ER Stress are the 
primary causes that drive hepatocytes from PiZZ individuals to eventual apoptosis (Lawless 
et al., 2008). Differentiated liver organoids from A1AT-D patients mimicked the in vivo 
situation and showed signs of ER stress, such as phosphorylation of eIF2α (Figure 7K) and a 
slight increase in apoptosis in the differentiated state (Figure S7C and D).  
 
Using a biopsy from a patient suffering from Alagille syndrome (AGS), we tested whether 
structural defects of the biliary tree can also be modeled. AGS is a rare genetic disorder 
caused by mutations in the Notch signaling pathway, which results in partial to complete 
biliary atresia (Kamath et al., 2013). Patient organoids could be expanded at normal rates and 
showed no obvious difference to donor in the undifferentiated state. However, upon 
differentiation to the biliary fate by withdrawal of R-spondin, Nicotinamide, TGFbi and FSK 
from the culture medium, AGS patient organoids failed to upregulate biliary markers such as 
KRT19 and KRT7, while donor (wildtype, wt) organoids readily did (Figure S7E). Staining 
for KRT19 revealed that biliary cells were reduced in numbers and were unable to integrate 
into the epithelium. Rather, they rounded up and underwent apoptosis inside the organoid 
(Figure S7F). This finding is in line with AGS mouse models, which show that Jagged-
1/Notch2 is dispensable for biliary lineage specification, but required for biliary 
morphogenesis (Geisler et al., 2008; McCright et al., 2002). Thus, AGS liver organoids 
mimic the patient phenotype and constitute the first human 3D model system to study Alagille 
syndrome. 
 
 
 
Discussion 
Liver diseases range from genetic inherited disorders (e.g. Alpha-1 antitrypsin or Alagille 
Syndrome) to viral hepatitis, liver cancer and obesity-related fatty liver disease. Overall, these 
account for the eighth-related cause of death in the United States (Asrani et al., 2013). Failure 
in the management of liver diseases can be attributed as much to the shortage of good quality 
donor livers (Vilarinho and Lifton, 2012) as to our poor understanding of the mechanisms 
behind liver pathology. The latter is mainly due to the lack of good in vitro models that allow 
the expansion of functional human liver cells that faithfully recapitulate the pathology of the 
associated disease.   
 
The value of any cultured cell as disease model or as a source for cell therapy transplantation 
depends as much as on the fidelity and robustness of its expansion potential as well as on its 
ability to maintain a normal genetic and epigenetic status (Pera, 2011). The possibility of 
differentiating hESC or reprogrammed fibroblasts (iPS) into almost any differentiated cell 
type, from neurons to hepatocytes, has allowed modeling of many human genetic diseases 
including A1AT-D (Rashid et al., 2010). However, the genetic instability of the cultured stem 
cells (as outlined in the Introductory section) raises concerns regarding their safe use in cell 
therapy transplantation (Bayart and Cohen-Haguenauer, 2013).  
 
Here, we show that primary human liver cells obtained from a donor liver can readily be 
expanded in vitro into 3D organoid cultures. These cells self-renew and differentiate into 
functional hepatocyte cells in vitro and generate bona-fide hepatocytes in vivo, upon 
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transplantation. Our extensive analysis of the genetic stability of cultured organoids in vitro 
demonstrates that the expanded cells preserve their genetic integrity after months in culture. 
 
Under our culture conditions, only ductal (but not hepatocyte) cells, acquire a bi-potent 
progenitor state and can differentiate into the two epithelial lineages of the liver: ductal and 
hepatocyte. These results agree with our previous observations in the mouse (Huch et al., 
2013b), yet are in striking contrast to recent publications where, utilizing several lineage 
tracing approaches, ductal/resident stem cells were shown little contribution to mouse liver 
regeneration (Schaub et al., 2014; Yanger et al., 2014; Yanger et al., 2013). While our 
experiments do not address the extent to which this ductal population contributes to 
physiological hepatocyte regeneration in humans, our results resemble what has been 
elegantly shown in zebrafish and rat models: in the event of an almost complete hepatocyte 
loss or blockage of hepatocyte proliferation, biliary epithelial cells convert into hepatocytes to 
regenerate zebrafish (Choi et al., 2014) and rat livers (Michalopoulos, 2014). Our data is 
further corroborated by recent observations made in human fulminant hepatic failure, where 
huge numbers of proliferating EpCAM+ biliary epithelial cells are observed (Hattoum et al., 
2013). These might be responsible for the rapid spontaneous recovery observed in some of 
these patients (up to 30%), by contributing to the generation of the de novo repaired 
hepatocyte pool (Michalopoulos, 2014). 
 
Furthermore, as a proof-of-concept, we show that the cells from patients suffering from an 
inherited metabolic liver disease, such as A1AT-deficiency, can be expanded in vitro and 
partially reproduce the features present on the A1AT-deficiency pathology. Translating such a 
system to the study of other inherited liver diseases, which often lack good in vitro and in vivo 
models, has the potential to increase our knowledge on the molecular pathogenesis of these, 
often abandoned, liver disorders. Indeed, we demonstrate that organoids derived from an 
Alagille Syndrome patient, a rare disorder affecting the architecture of the liver biliary tree, 
can be readily expanded and reproduce the structural duct defects present in the livers of these 
patients. Repair by homologous recombination using CRISPR/Cas9 technology is feasible in 
organoid cultures, as we have recently demonstrated in colon stem cells of Cystic Fibrosis 
patients (Schwank et al., 2013). A variety of monogenic hereditary diseases affect the liver 
specifically, and these should all be amenable to a comparable in vitro approach of gene 
repair in clonal liver stem cells, thus opening up the avenue to design personalized treatments 
for these patients. Overall, our results open up the avenue to start testing human liver material 
expanded in vitro as an alternative cell source for studies of human liver regeneration, human 
liver disease mechanism, cell therapy transplantation, toxicology studies or drug testing.  
 
 
 
Experimental Procedures 
 
Human liver organoid culture 
Liver biopsies (0.5-1cm3) were obtained from donor and explant livers during liver 
transplantation performed at the Erasmus MC, Rotterdam. The Medical Ethical Council of the 
Erasmus Medical Center approved the use of this material for research purposes and informed 
consent was provided by all patients. Liver cells were isolated from human liver biopsies 
(0.5-1cm3) by collagenase-accutase digestion as described in Supplemental Experimental 
Procedures. The different fractions (collagenase and accutase) were mixed and washed with 
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cold Advanced DMEM/F12 and spun at 300-400g for 5 min. The cell pellet was mixed with 
Matrigel (BD Biosciences) or Reduced Growth Factor BME 2 (Basement Membrane Extract, 
Type 2, Pathclear) and 3000-10000 cells were seeded per well in a 48well/plate. Non-
attaching plates were used (Greiner). After Matrigel or BME had solidified, culture medium 
was added. Culture media was based on AdDMEM/F12 (Invitrogen) supplemented with 
1%N2 and 1%B27 without retinoic acid (both from Gibco), 1.25 mM N-Acetylcysteine 
(Sigma), 10 nM gastrin (Sigma) and the growth factors: 50 ng/ml EGF (Peprotech), 10% 
RSPO1 conditioned media (home-made), 100 ng/ml FGF10 (Peprotech), 25ng/ml HGF, 
10mM Nicotinamide (Sigma), 5uM A83.01 (Tocris) and 10uM FSK (Tocris). For the 
establishment of the culture, the first 3 days after isolation the medium was supplemented 
with 25ng/ml Noggin (Peprotech), 30% Wnt CM (home-made prepared as described in 
(Barker et al., 2010) and 10 uM (Y27632, Sigma Aldrich) or hES Cell cloning Recovery 
solution (Stemgent).  Then, the medium was changed into a medium without Noggin, Wnt, 
Y27632, hES Cell cloning Recovery, solution while 25ng/ml BMP7 (Peprotech) were 
supplemented on top. The latter addition is optional. After10-14 days organoids were 
removed from the Matrigel or BME, mechanically dissociated into small fragments, and 
transferred to fresh matrix. Passage was performed in 1:4-1:8 split ratio once every 7-10 days 
for at least 6 months. To prepare frozen stocks, organoid cultures were dissociated and mixed 
with Recovery cell culture freezing medium (Gibco) and froze following standard procedures. 
When required, the cultures were thawed using standard thawing procedures and cultured as 
described above. For the first 3 days after thawing, the culture medium was supplemented 
with Y-27632 (10 μM). 
Growth curves and expansion ratios were performed and calculated as described in 
Supplemental Experimental Procedures. 
 
Isolation of EpCAM+ cells and single cell (clonal) culture 
Cell suspensions prepared as described in Supplemental Experimental Procedures were 
stained with Anti-Human CD326 (EpCAM), sorted on a MoFlo (Dako Cytomation) sorter 
and cultured as described above with medium supplemented with Y-27632 (10 μM, Sigma 
Aldrich) for the first 4 days. Passage was performed in split ratios of 1:4-1:8 once per week  
For clonogenic assays, single cell suspensions were sorted using FSC and pulse width to 
discriminate single cells. Propidium iodide staining was used to label dead cells and FSC: 
Pulse-width gating to exclude cell doublets (MoFlow, Dako). Sorted cells were embedded in 
Matrigel and seeded in 96 well plates at a ratio of 1 cell/well. Cells were cultured as described 
above. 
 
Hepatocyte differentiation and in vitro functional studies 
Liver organoids were seeded and kept 7-10 days under the liver expansion conditions 
explained above supplemented with BMP7 (25ng/ml). Then, the cultures were split and 
seeded accordingly in this expansion medium supplemented with BMP7 for at least 2-4 days. 
Then, medium was changed to the differentiation medium (DM): AdDMEM/F12 medium 
supplemented with 1%N2 and 1% B27 without retinoic acid (both from Gibco) and 
containing EGF (50 ng/ml), gastrin (10nM, Sigma), HGF (25ng/ml, Peprotech), FGF19 (100 
ng/ml), A8301 (500 nM, Tocris Bioscience), DAPT (10 uM, Sigma), BMP7 (25ng/ml) and 
Dexamethasone (30uM). Differentiation Medium was changed every 2-3 for a period of 11-
13 days.  
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To assess hepatocyte function culture medium was collected 24h after the last medium 
change. Functional studies were performed in the collected supernatant or in whole organoids 
as described in Supplemental Experimental Procedures.  
 
Transplantation 
We used a modified version of the protocol used by Guo et al. (Guo et al., 2002). In short, 
female BALB/c nude mice (around 7 weeks of age) were pretreated with two injections of 70 
mg/kg Retrorsine (Sigma) at 30 and 14 days before transplantation. One day prior to 
transplantation, mice received 0.5 ml/kg CCl4 and 50 mg/animal anti-asialo GM1 (Wako pure 
chemical industries) via IP injection. Furthermore, animals received 7.5 ug/ml FK506 in 
drinking water until the end of the experiment, due to the reported positive effects on liver 
regeneration (He et al., 2010). On the day of transplantation, mice were anaesthetized and 
suspensions of 1-2x106 human liver organoid cells derived from 4 independent donors (p6 to 
p10) were injected intrasplenically. Transplanted mice received weekly injections of 50 
mg/animal anti-asialo GM1 (Wako pure chemical industries) to deplete NK cells. To monitor 
the transplantation state, blood samples were taken in regular intervals from the tail vein and 
analyzed for the presence of human albumin and human α1-antitrypsin using respective 
human specific ELISAs (Assaypro). 
 
Karyotyping and Genetic stability analysis  
Organoid cultures in exponential growing phase were incubated for 16 hours with 0.05 μg/ml 
colcemid (Gibco). Then, cultures were dissociated into single cells using TrypLE express 
(Gibco) and processed using standard karyotyping protocols.  
DNA libraries for WGS analysis were generated from 1 g of genomic DNA using standard 
protocols (Illumina). The libraries were sequenced with paired-end (2 x 100 bp) runs using 
Illumina HiSeq 2500 sequencers to a minimal depth of 30 x base coverage (average depth of 
~ 36.9 x base coverage). As reference sample, liver biopsies was sequenced to equal depth for 
the different donors. Analysis of the sequence reads, calling of CNVs and base substitutions 
are described in detail in Supplemental Experimental Procedures. The data for the whole 
genome sequencing were deposited to the EMBL European Nucleotide Archive, accession 
number ERP005929. 
 
Immunohistochemistry, immunofluorescence and Image analysis 
Tissues and organoids were fixed o/n with formalin or 4% PFA respectively, and stained and 
imaged as described in Supplemental Experimental Procedures.  
 
A1AT-D functional experiments 
Elastase inhibition assay, and detection of phosphorylated of eIF2α were performed as 
described in Supplemental Experimental Procedures. 
 
Microarray 
For the expression analysis of human liver cultures, total RNA was isolated from liver 
biopsies or from organoids cultures grown in our defined medium, using Qiagen RNAase kit 
following manufacture’s instructions. Five hundred ng of total RNA were labeled with low 
RNA Input Linear Amp kit (Agilent Technologies, Palo Alto, CA). Universal human 
Reference RNA (Agilent) was differentially labeled and hybridized to the tissue or cultured 
samples. A 4X 44 K Agilent Whole Human Genome dual colour Microarray (G4122F) was 
used. Labeling, hybridization, and washing were performed according to Agilent guidelines. 
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Microarray signal and background information were retrieved using Feature Extraction 
software (V.9.5.3, Agilent Technologies). The hierarchical clustering analysis was performed 
in whole liver tissue lysate or organoid arrays. A cut-off of 3-fold differentially expressed was 
used for the clustering analysis. GEO accession number pending. 
 
Data analysis 
All values are represented as mean ± standard error of the mean (S.E.M.). Man-Whitney non-
parametric test was used. p<0.05 was considered statistically significant. In all cases data 
from at least 3 independent experiments was used. All calculations were performed using 
SPSS package. 
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Figure Legends 
 
Figure 1: Human liver biopsies grow long term as epithelial organoids from ductal 
origin 
Human liver cells were isolated from biopsies from liver donor material by collagenase 
dissociation. Tissues were dissociated to single cell and 3000 or 10000 cells were seeded per 
well in a 48well plate in different culture conditions as indicated on the Figure. (A) Scheme 
of the experimental protocol. (B) Cells were seeded in different culture conditions as follows: 
mouse liver culture medium (ERFHNic) or medium supplemented with A8301 or A8301 and 
Forskolin (FSK) as indicated and organoids were allowed to grow. The cultures were split 
every week 7-10 days at a ratio of 1:4 -1:6 dilution.  Cells started to proliferate however, the 
cultures grown in mouse medium or medium supplemented with A8301 only arrested 
proliferation after some weeks in culture and could not be expanded any further as indicated 
in the graph. Supplementing the culture medium with A8301 combined with FSK 
significantly increased the expansion efficiency of the cultures which have been able to grow 
for >18 passages at a split ratio of 1:4-1:6 every 7-10 days for >5 months. Experiments were 
performed in triplicate. Each bar indicates a different donor starting material. (C) DIC images 
of organoids treated with mouse liver medium +A8301 and supplemented (right panel) or not 
(left panel) with FSK. (D) Graph indicating the % of colony formation efficiency in cultures 
seeded in the presence or absence of A8301 and or FSK. Experiments were performed in 
triplicate. Five different donor derived cultures were counted. Results are expressed as mean 
± SEM of 5 independent experiments. (E-G) To quantify the proliferation capacity of the 
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human liver cultures, expansion ratios, in vitro growth curves and EdU incorporation, at early 
and late passages, were analyzed in human liver cultures grown in complete medium 
(ENRFHNic + A8301 and FSK). (E-F) Cell numbers were counted by Trypan blue exclusion 
at the indicated time points, in at least triplicates of 3 independent human donor materials. 
The cultures followed an exponential growth curve within each time window analyzed. 
Graphs illustrate the number of cells counted per well at each passage from P1-P4 (E) to P16-
P18 (F). The doubling time, or amount of time the culture needs to double its original size, 
was calculated as described in Supplemental Experimental Procedures. Note that the doubling 
time was essentially maintained once the culture had started to expand (from day 16 
onwards). (G) Similarly, EdU incorporation was still detected at late passages, again 
indicating that the cells maintain their proliferation potential in vitro after long-term culturing. 
(H) Human liver cell suspensions were separated into EpCAM+ ductal cells and larger, 
EpCAM- hepatocytes (for exact gating strategy see Figure S2C). Identity of the populations 
was confirmed by cytospins and subsequent IF staining for Albumin and KRT19. Sorted cells 
were seeded into matrigel and grown for 14 days into organoids. Organoids were exclusively 
derived from EpCAM+ ductal cells. See also Figure S1 and Figure S2. 
 
Figure 2: Human organoids are genetically stable after months of expansion in culture 
Genetic stability of human liver cultures was analyzed in clonally grown cultures that had 
been expanded for > 3 months (~120 days) in our complete human liver medium.  (A) Human 
liver biopsies were dissociated into single cells and clonal cultures were obtained by seeding 
sorted cells at a ratio of 1 cell per well. As illustrated, cells quickly proliferated and expanded 
in culture. DIC images of growing single cells from human liver cultures. Magnifications: 
40x (days 0-10), 4x (day 20-onwards). (B-D) Genetic stability of the human liver organoid 
cultures clonally expanded long-term in vitro. (B) Schematic overview of the experimental 
setup. Two independent donor liver biopsies were minced and cultured for one week. 
Subsequently, single liver stem cells were isolated and clonally expanded to obtain two 
independent organoid cultures per donor (culture A and culture B). These cultures were 
subjected to long-term expansion after which a second clonal expansion step was performed. 
The resulting organoid cultures were subjected to whole genome sequencing (WGS) analysis. 
To obtain all somatic variation present in the cultures, variants were filtered for presence in 
the original biopsy. To determine the effect of long-term culturing on genomic stability, 
somatic variation was filtered for presence in earlier passages. (C) Number of somatic base 
substitution observed in the different organoid cultures. The pie-chart indicates the percentage 
of the genome that was surveyed per donor. The right panels indicate the absolute numbers of 
base substitution observed in the surveyed part of the genome. Indicated are the total number 
of somatic base substitutions per culture and the number induced by long-term culturing. (D) 
Effect of somatic base substitutions on protein-coding DNA. Left panels indicate the total 
number of somatic base substitutions per donor and the left panel indicates the part that 
affects protein-coding DNA.  See also Figure S3.     
 
Figure 3. Structural variation in human liver organoids. 
(A) Representative karyotyping image of organoids cultured for 16 days (P1) and 90 days 
(P14) illustrating a normal chromosomal count (n=46). No major chromosomal aberrations 
were observed in any of the samples analyzed (n=15). Detailed chromosomal counts for 
different donors are shown in supplemental Figure S4. (B) Read-depth analysis of whole 
genome sequencing data over the different chromosomes for the biopsy (upper panel) and 
organoid culture A (lower panel) that were derived from donor 2. Read-depth was corrected 
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for GC content and normalized for genome coverage. Grey dotted lines indicate log2 values 
associated with a gain or deletion. (C) Copy number analysis of a region at chromosome 3 
that was found to harbor a heterozygous gain in culture A of donor 2. Left panels indicate 
read-depth analysis of the indicated region in 5kb bins, corrected for GC content and 
normalized for genome coverage, of the biopsy (upper panel) and organoid culture (lower 
panel). Right panels show the variant allele frequencies of informative non-reference single 
nucleotide polymorphisms (SNPs) in the indicated region for the biopsy (upper panel) and 
organoid culture (lower panel). (D) Summary of the copy number analysis of the different 
organoid cultures of the two donors. Somatic CNVs were exclusively observed in culture A 
derived from donor 2, which were already present in the parental culture. See also Figure S4. 
 
Figure 4: Human liver organoids express LGR5 and markers of the ductal and 
hepatocyte lineages 
Gene expression was analyzed by RT-PCR (A) and immunofluorescence (B) in human liver 
cultures grown in our defined expansion medium as described in Experimental Procedures. 
(A) Gene expression was analyzed at early (EP) and late (LP) passages. Human liver cultures 
expressed progenitor (LGR5, SOX9), ductal (KRT19, SOX9) and hepatocyte (HNF4A) 
markers but they do not express albumin (ALB) while in expansion medium. Results are 
indicated as 2-dCt (2ΔΔCT). Values represent mean ± SEM of 3 independent experiments in 5 
independent donor derived cultures. 2ΔΔCT were calculated using the housekeeping gene 
GAPDH as reference gene for normalization. (B-F) Confocal images of a human liver 
organoid showing that the organoids are formed by epithelial derived structures positive for 
ECAD and the hepatocyte marker HNF4 (B), and the ductal markers (KRT19, C; KRT7, D) 
and SOX9 (E). Nuclei were counterstained with Hoechst. (F) Confocal images of a human 
liver organoid showing that the organoids are formed by epithelial derived cells positive for 
EPCAM (blue). The stem cell marker Lgr5 (green) was restricted to a subset of cells within 
the organoid, while the Wnt target gene EPHB2 (red) was broadly expressed, but co-localized 
with LGR5, as expected. See also Figure S5. 
 
Figure 5: Upon Differentiation, organoid cultures upregulate hepatocyte genes 
Human liver cultures were expanded for at least 1 month in culture and transferred to our 
differentiation medium as described in Experimental Procedures. (A) Scheme of the 
experimental plan. (B-C) Expression of hepatocyte genes was determined by 
immunofluorescence (B) or qPCR (C) 11 days later. (B) Immunofluorescence staining 
showing albumin (ALB, red) and zona occuludens (ZO-1, green) positive cells all over the 
organoid, indicating that the cells start expressing hepatocyte markers. (C) qPCR analysis 
indicated that both, albumin and Cytochrome p450 3A4 isoform were highly expressed upon 
differentiation. Graphs indicate mean ± SEM of 3 independent experiments in 3 independent 
donor derived cultures. EM, expansion medium including FSK. DM, differentiation medium, 
Tissue, whole lysate from human liver. **, p<0,01 when comparing EM vs DM. (D) Whole 
genome transcriptome analysis of human liver cultures grown in our expansion medium (EM) 
or after being cultured 11 days in our defined Differentiation medium (DM). Heat map 
indicates cluster of genes highly expressed in liver tissue and in organoid cultures upon 
differentiation. Of note, this cluster contains genes essential for liver function, as the indicated 
in red. Green, downregulated; Red, upregulated. See also Figure S5. 
 
Figure 6: Liver cultures exhibit hepatocyte functions in vitro and in vivo 
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To test whether the cells could have differentiated towards functional hepatocytes in vitro, we 
determined the ability of the cultures to retain some hepatocyte functions in vitro, upon 
differentiation. (A), Glycogen accumulation was determined by PAS (Periodic-Acid Schiff) 
staining in organoids grown in EM or DM for 11 days. PAS positive staining (pink) was 
exclusively observed in the organoids after Differentiation (DM), indicating that the cells 
exhibit capacity to accumulate glycogen. Magnification, 10x. (B) LDL uptake was analyzed 
using Dil-ac-LDL fluorescent substrate (red) in cultures maintained in EM (left) or DM 
(right) for 11days. Only cultures maintained in DM incorporated the substrate (red). Nuclei 
were counter-stained with DRAQ5. Scale bar, 25 µm. (C) Albumin production during 24h 
was measured in the supernatant of liver organoids. Results are expressed as mean ± SEM of 
2 independent experiments in 4 independent donor-derived cultures.  (D) CYP3A4 activity 
was measured as described in methods in cultures kept in DM for 11 days. Results are 
expressed as RLU per ml per million cells. HEK293T cells and HepG2 cells were used as 
negative and positive controls respectively. Note that organoids upon DM exhibit similar the 
CYP3A4 activity as fresh isolated hepatocytes (see Figure S2A). Triplicates for each 
condition were analyzed. Results are shown as mean ± SEM of 2 independent experiments in 
4 independent donor-derived cultures. (E), Midazolam metabolism is performed exclusively 
by functional CYP3A3/4/5 enzymes.  3 different organoid cultures from 2 different donors 
and HepG2 cells were plated and cultured for 11 days as described, then midazolam was 
added to the medium (5M) and after 24 hours, concentrations of 1-OH midazolam and 1-OH 
midazolam glucuronide were determined as described in methods. Duplicates for each 
condition and donor were analyzed. Results are shown as mean ± SEM of 2 independent 
experiments. (F) Bile acid production was measured as described in methods. Results are 
shown as ± SEM of 2 independent experiments in 2 independent donor-derived cultures. 
Duplicates for each condition and donor were analyzed. (G) Ammonia elimination was 
measured as described in methods. Results are shown as ± SEM of n=3 independent 
experiments in 2 independent donor-derived cultures and are expressed as nM/h/million cells. 
(H) Retrorsine/CCl4 treated Balbc/nude mice were transplanted with 1-2x10
6 human liver 
organoid cells and sacrificed after 120 days. The presence of foci of human Albumin positive, 
but human KRT19 negative hepatocytes proves successful engraftment and differentiation in 
mouse liver. (I) Average serum levels of human Albumin in mouse circulation after 
transplantation. Results are shown as ± SEM of 2 vehicle control animals, 2 primary 
hepatocyte transplanted mice and 6 human liver organoid transplanted animals.  **, p<0,01 
and *, p<0,05 when comparing EM vs DM. See also Figure S6. 
 
Figure 7: Human A1AT deficiency Liver cultures as an in vitro disease model  
 (A) Representative pictures of A1AT deficient patient derived liver organoids at Passage 2 
and Passage 11 (4x magnification). (B) ELISA measurement of Albumin secretion in 
supernatant from donor and A1AT deficient patient organoids in EM or after 11 days in DM. 
Patients and donors show a similar level of albumin release. Results are expressed as mean ± 
SEM of 2 independent experiments. (C) A1AT deficient patient organoids were differentiated 
for 11 days and incubated with DiI-Ac-LDL as described in materials and methods. 
Fluorescence microscopy shows robust LDL uptake in patient organoids. Scale bar, 50 µm 
(D) Fold induction of Albumin and CYP3A4 mRNA levels after 11 days of differentiation of 
donor and A1AT deficient patient organoids. Results are expressed as mean ± SEM of 2 
independent experiments (E-H) Immunohistochemistry for A1AT on liver tissue (E/G) and 
liver derived organoids from a healthy donor (F) and a representative A1AT deficient patient 
(H). Arrows indicate A1AT protein aggregates in patient derived liver tissue (G) and 
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organoids (H). Scale bar, 20 µm. (H) ELISA measurement of A1AT secretion in supernatants 
from Donor and patient organoids after 11 days of differentiation. Results are expressed as 
mean ± SEM of 2 independent experiments. (I) Enzymatic measurement of Elastase 
inhibition by supernatants of differentiated donor and patient derived organoid cultures (as 
described in materials and methods). Supernatants from all 3 patients show reduced inhibition 
of Elastase activity. Results are expressed as mean ± SEM of 2 independent experiments (J) 
Western blot of total lysates from donor and A1AT deficient patient organoids after 11 days 
of differentiation. Increased eIF2α phosphorylation at Ser51 was detected in the 3 patients. 
Representative image is shown. Pat., patient. See also Figure S7. 
 
 
 
EpCAM-
EpCAM+
EpCAM-488
P
I
B
EdU
Hoechst
P12
days 
donor_1 
0 5 10 15 20 
ERFHNic  
 +A 
++A  + FSK   
donor_3 
donor_2 
 N of passage (weeks in culture)
ERFHNic + A ERFHNic + A + FSK
C D
G
%
 o
rg
an
oi
d 
fo
rm
at
io
n 
E
R
FH
N
ic
0.00%
0.20%
0.40%
0.60%
0.80%
1.00%
1.20%
E
R
FH
N
ic
 +
A
E
R
FH
N
ic
 +
A 
+ 
FS
K
E F
1.0E+04 
4.0E+06 
8.0E+06 
1.2E+07 
1.6E+07 
0 5 10 15 20 25 30 35 
1.0E+04 
5.1E+05 
1.0E+06 
1.5E+06 
2.0E+06 
2.5E+06 
85 90 95 100 105 
days 
isolation - passage
doubling time
day23-30= 62h +/- 0.3h
serially passaged
doubling time
day83-93= 66.1h +/- 7.2h
A
Budding
Organoid 
Lumen
3D-culturebiopsy 
(~1cm3) serial 
expansion
Figure 1:
 
Human liver biopsies grow long term as epithelial organoids of ductal origin
50 µm
Albumin
Krt19
50 µm
Albumin
Krt19
1 mm
1 mm
d14 organoid cultureH
Figure1
Click here to download Figure: revised Fig 1.pdf 
Liver
biopsy
7 days
culture
WGS
WGS WGS
Stem cell B
Stem cell A
Subclone A
Subclone B
All somatic variation
Long-term culturing effects
Long-term expansion
C D
D
O
N
O
R
 1
(a
ge
 7
4 
ye
ar
s)
D
O
N
O
R
 2
(a
ge
 3
0 
ye
ar
s)
59.8%
0 400 800 1200 1600 2000
No. of somatic base substitutions
0 400 800 1200 1600 2000
No. of somatic base substitutions
1424
720
850
1263
Culture A
Culture B
Culture A
Culture B
66.5%
Surveyed part of the genome Non-coding base substitutions
Coding base substitutions
Nonsynonymous base substitutions
Synonymous base substitutions
Base substitutions at splice sites
Not surveyed part of the genome
All somatic base substitutions
Somatic base substitutions during long-term culturing
+
2671 16
17
13
13
3
3
1
DONOR 1
DONOR 2
1552
1 month (P2) 4,5 months (P16) day 5 day 20 (P1) day 0 day 2.5 day 10A
B
Figure 2:  Human organoids are genetically stable after months of expansion in culture
Figure2
Click here to download Figure: revised Fig 2.pdf 
AC
D
B
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Chromosome
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22
Chromosome
R
ea
d 
de
pt
h 
(lo
g2
ra
tio
)
0.0
0.5
-0.5
-1.0
-1.5
1.0
1.5
R
ea
d 
de
pt
h 
(lo
g2
ra
tio
)
0.0
0.5
-0.5
-1.0
-1.5
1.0
1.5
R
ea
d 
de
pt
h 
(lo
g2
ra
tio
)
0
1
-1
-2
2
R
ea
d 
de
pt
h 
(lo
g2
ra
tio
)
0
1
-1
-2
2
Donor 2, Biopsy
Donor 2, Culture A late passage
Position on chromosome 3
111,500,000 112,000,000 112,500,000 113,000,000 113,500,000
Position on chromosome 3
111,500,000 112,000,000 112,500,000 113,000,000 113,500,000
Position on chromosome 3
111,500,000 112,000,000 112,500,000 113,000,000 113,500,000
Position on chromosome 3
111,500,000 112,000,000 112,500,000 113,000,000 113,500,000
Va
ria
nt
 a
lle
le
 fr
eq
ue
nt
y 
S
N
P
s
0
0.2
0.4
0.6
0.8
1.0
Va
ria
nt
 a
lle
le
 fr
eq
ue
nt
y 
S
N
P
s
0
0.2
0.4
0.6
0.8
1.0
Donor 2, Culture A
Donor
1
2
Culture
A
B
A
B
CNV
0
0
2
0
Location
N/A
N/A
chr3:94,491,001-95,652,000
chr3:111,725,000-113,472,000
N/A
Present at early passage
N/A
N/A
Yes
Yes
N/A
Type
N/A
N/A
Gain
Gain
N/A
Passage 1 (2 weeks in culture)
Passage 14 (12 weeks serial expansion)
Figure 3. Structural variation in human liver organoids.
Donor 2, Biopsy
Figure3
Click here to download Figure: Fig3final.pdf 
EpCAM/ LGR5/ EPHB2 
HNF4a ECAD Hoechst 
 
KRT19 Hoechst 
 
KRT7 Hoechst 
 
SOX9 
F
B C
D E
A
0.0 
5.0 
10.0 
15.0 
20.0 
25.0 
30.0 
35.0 
40.0 
45.0 
EP LP Tissue 
0.0E+00 
5.0E-04 
1.0E-03 
1.5E-03 
2.0E-03 
2.5E-03 
EP LP Tissue 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
EP LP Tissue 
0 
0.005 
0.01 
0.015 
0.02 
0.025 
EP LP Tissue 
0 
0.00002 
0.00004 
0.00006 
0.00008 
0.0001 
0.00012 
0.00014 
0.00016 
EP LP Tissue 
0 
0.00001 
0.00002 
0.00003 
0.00004 
0.00005 
0.00006 
0.00007 
0.00008 
EP LP Tissue 
LGR5 AXIN2
SOX9
HNF4a
KRT19 ALB
2d
C
T
2d
C
T
2d
C
T
2d
C
T
2d
C
T
2d
C
T
Figure 4: Human liver organoids express LGR5 and markers of the ductal and hepatocyte 
lineages
Figure4
Click here to download Figure: Fig4.pdf 
day-7
EM + 
BMP7 
day0
DM
day11
analysis
A
C D
B ZO1  Alb  Hoecsht  MRP4 Hoecsht
Figure 5: Upon Differentiation, organoid cultures upregulate hepatocyte genes.
day15
EM serial 
expansion
LGR5 KRT19
ALB CYP3A4
1.E-01 
1.E+00 
1.E+01 
1.E+02 
1.E+03 
1.E+04 
1.E+05 
1.E+06 
EM DM Tissue 
0.00 
0.50 
1.00 
1.50 
2.00 
2.50 
3.00 
3.50 
4.00 
EM DM Tissue  
0 
1 
10 
100 
1000 
10000 
EM DM Tissue  
0.00 
0.20 
0.40 
0.60 
0.80 
1.00 
1.20 
1.40 
EM DM Tissue  
tis
su
e 
_1
tis
su
e_
2
tis
su
e_
3
tis
su
e_
4
EM
_2
EM
_1
EM
_3
EM
_4
D
M
_1
D
M
_2
D
M
_3
D
M
_4
EM
_5
HAMP
DCN
CES1
C2
LEAP2
C4BPA
APOA1
APOB
APOC3
RBP4
TTR
FGL1
FGA
F2
ALB
C3
Fo
ld
 c
ha
ng
e 
D
M
/E
M
**
**
**
Figure5
Click here to download Figure: Fig5.pdf 
EM DM
A B
EM DM
LDL-uptakeGlycogen storage
Figure 6: Liver cultures exhibit hepatocyte functions in vitro and in vivo 
C Albumin secretion
0.00
100.00
200.00
300.00
400.00
500.00
ng
 A
LB
/d
ay
/1
06
 c
el
ls **
0.00E+00
5.00E+05
1.00E+06
1.50E+06
2.00E+06
2.50E+06
3.00E+06
3.50E+06
4.00E+06
D CYP3A4 activity 
R
LU
/m
l/1
06
 c
el
ls
29
3T
He
pG
2
EM DM
**
hAlbumin hKRT19
200 μm 200 μm
H I
He
pG
2 
DM
 0 
0.2 
0.4 
0.6 
0.8 
1 
1.2 
1.4 
1.6 
1.8 
2 
EM
 
1-OH midazolam   
1-OH midazolam 
glucuronide  
Midazolam metabolismE
m
g/
 m
l/ 
10
6  
ce
lls
*
F G
He
pG
2 
0 
1 
2 
3 
4 
5 
6 
7 
EM
 
DM
 
Bile Acid production
B
ile
 a
ci
ds
 u
M
/ 1
06
 c
el
ls
Ammonia Elimination
0 
5 
10 
15 
20 
25 
EM DM HepaRG 
A
m
m
on
ia
 n
M
/ h
/ 1
06
 c
el
ls*
Av
er
ag
e 
bl
oo
d 
hA
lb
um
in
 le
ve
ls
 
in
 s
uc
es
sf
ul
ly
 e
ng
ra
fte
d 
m
ic
e 
(n
g/
m
l)
days after transplantation
Vehicle control
Hepatocyte transplanted
Liver Organoid transplanted
0 10 20 30 40
0
50
100
150
1250
1500
1750
2000
Figure6
Click here to download Figure: revised Fig 6new.pdf 
A1AT-D culture (20 days) A1AT-D culture (120 days)
LDL uptake
A B
C D
I
J
EM
DM
Do
no
rs
A1
AT
-D
pa
t. 1
0
200
400
600
800
1000
A1
AT
-D
pa
t. 2 A1
AT
-D
pa
t. 3He
pG
2
29
3Ts
ec
re
te
d 
A
lb
um
in
/1
06
 c
el
ls
 (n
g)
6 
ce
lls
 (A
U
)
E
la
st
as
e 
in
hi
bi
tio
n/
10
0
1000
2000
3000
Elastase inhibition
Do
no
rs
A1
AT
-D
pa
t. 1 A1
AT
-D
pa
t. 2 A1
AT
-D
pa
t. 3
0
400
800
1200
se
cr
et
ed
 α
1A
T/
10
6 
ce
lls
 (n
g)
Do
no
rs
A1
AT
-D
pa
t. 1A1
AT
-D
pa
t. 2 A1
AT
-D
pa
t.3He
pG
2
29
3T
A1AT secretionDonor (A1AT) A1AT-D Pat. 1 (A1AT)
Li
ve
r T
is
su
e
O
rg
an
oi
d
1
10
100
1000
EM Albumin
EM Cyp3a4
DM Albumin
DM Cyp3a4
Donors A1AT-D
pat. 1
A1AT-D
pat. 2
A1AT-D
pat. 3
fo
ld
 c
ha
ng
e 
D
M
 v
s 
E
M
 
3
Donor A1AT-D pat.
P-eIF2α (Ser51)
eIF2 α
GAPDH
1 2 3 1 2
K
Figure 7: Human A1AT deficiency liver cultures as an in vitro disease model 
E
F
G
H
Donor (A1AT) A1AT-D Pat. 1 (A1AT)
Figure7
Click here to download Figure: Fig7.pdf 
 1 
Supplemental Information 
 
Supplemental Data 
Figure S1: TgFb inhibition, active Wnt signaling and cAMP activation are essential for 
the long term expansion of human liver cells. Related to Figure 1 
 
Figure S2: Human liver cultures are of ductal origin. Related to Figure 1 
 
Figure S3: Filtering steps and FNR of all sequenced samples. Related to Figure 2 
 
Figure S4: Genetic stability of human liver stem cell cultures. Related to Figure 3 
 
Figure S5: Analysis of organoids during expansion and upon differentiation. Related to 
Figure 5 and 6 
 
Figure S6: Transplantation of human liver organoids into damaged mouse liver. Related 
to Figure 6. 
 
Figure S7: Organoids from A1AT-Deficiency and AGS patients mimic disease 
phenotypes in vitro. Related to Figure 7.  
 
Table S1: List of tested compounds. Related to Figure 1 
List of all the compounds tested for their capacity to enhance human liver culture 
proliferation, long-term maintenance or differentiation. Human liver cultures were seeded in 
ERFHNic medium supplemented with A8301 and the compound indicated on the list. 
Seeding efficiency and capacity to expand long-term the cultures was evaluated. Green, the 
compound supports human liver growth. Red, the compound has a negative effect on the 
culture. Absence of color, the compound does not affect either way.  
 
Table S2: Human material cultured. Related to Figure 1-7. 
Patient and donor information from the cultured material. When available, A1AT protein 
serum levels are listed 
 
Table S3: List of mutated genes with non-synonymous mutations found after WGS 
analysis. Related to Figure 2 
 
Table S4: List of primers used. Related to Experimental Procedures 
 
Table S5: List of antibodies used. Related to Experimental Procedures 
 
 
Supplemental Experimental Procedures 
Human liver isolation 
Liver cells were isolated by collagenase digestion as follows: tissue (0.5-1cm3) was minced, 
rinsed 2x with DMEM (Gibco) 1%FCS and incubated with the digestion solution (2.5 mg/ml 
collagenase D (Roche) + 0.1 mg/ml DNase I (Sigma) in EBSS (Hyclone, Thermoscientific), 
for 20-40 at 37°C. The digestion was stopped by adding cold DMEM 1%FCS and the 
suspension was then filtered through a 70 um Nylon cell strainer and spun 5 min at 300-400g. 
Supplemental Information (compiled Word file)
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The pellet was resuspended in DMEM 1%FCS and kept cold. Any material retained on the 
strainer was further digested for 10 min in Accutase (Gibco) at 37C. Then, the digestion was 
stopped and the cells were collected as before. The different fractions (collagenase and 
accutase) were seeded and cultured as described in Experimental Procedures. 
 
In vitro growth curves 
Expansion ratios were calculated from human liver cultures as follows: 3x103 cells were 
grown in our defined medium for 7 or 10 days. Then, the cultures were dissociated by 
incubation with TrypLE Express (Gibco) until single cells. Cell numbers were counted by 
trypan blue exclusion at the indicated time points. From the basic formula of the exponential 
curve y(t) = y0 x  e
(growth rate x t ) (y = cell numbers at final time point; y0 = cell numbers at initial 
time point; t = time) we derived the growth rate. Then, the doubling time was calculated as 
doubling time = ln(2)/growth rate for each time window analyzed. 
 
Isolation of EpCAM+ cells from primary human liver 
Human liver cells were isolated according to standard protocol at the liver cell laboratory at 
the unit for transplantation surgery, CLINTEC, Karolinska Institute. Cell suspensions were 
shipped overnight on ice. Suspensions were diluted in 2 volumes of cold Advanced 
DMEM/F12 (Gibco) and washed 3 times in the same medium. Viable cells were counted with 
Trypan blue and split into 3 parts for EpCAM sorting, Percoll purification (see Hepatocyte 
Percoll purification) and direct seeding into matrigel. For sorting, liver cells were stained with 
1:100 Anti-Human CD326 (EpCAM) Alexa Fluor® 488 (eBioscience) for 30 minutes at 4°C. 
Subsequently cells were washed and sorted on a MoFlo (Dako Cytomation) cell sorter. Sorted 
cells were spun down, resuspended in Matrigel and grown into organoids according to 
standard human liver organoid culture procedure (see Human liver organoid culture). After 14 
days in culture the number of organoids larger than 100 µm in diameter was scored. 
 
Hepatocyte Percoll purification and Cyp3a4 measurement 
Human hepatocyte suspensions (see Isolation of EpCAM+ cell from primary human liver) 
were washed as described, spun down and resuspended in 35 ml Advanced DMEM/F12 
(Gibco) + 13.5 ml Percoll (GE healthcare, density 1.130 g/ml) + 1.5 ml 10x HBSS (GIBCO). 
Cells were pelleted at 100 g for 10 minutes and washed 3 times in Advanced DMEM/F12 
(Gibco). Viable cells were counted with Trypan blue and 10.000 viable cells per 50 ul drop 
were seeded into matrigel. Remaining cells were stained for EpCAM as described above (see 
Isolation of EpCAM+ cells from primary human liver) or seeded onto collagen coated tissue 
culture plates for subsequent determination of cytochrome 3A4 activity. To measure Cyp3a4 
in primary hepatocytes, the seeded cells were cultured in Williams E medium (Gibco) 
containing Hepatocyte plating supplement pack (Gibco) for 4 days with daily medium 
changes. On day 0 and day 4 the cells were incubated with Luciferin-PFBE substrate (50 µM) 
and Cytochrome P450 activity was measured using the P450-Glo Assay Kit (Promega) 
according to manufacturer’s instructions and normalized to the number of cells in the plate. 
HepG2 cells cultured in the same medium served as controls.  
 
Genetic analysis 
DNA libraries for WGS analysis were generated from 1 g of genomic DNA using standard 
protocols (Illumina). The libraries were sequenced with paired-end (2 x 100 bp) runs using 
Illumina HiSeq 2500 sequencers to a minimal depth of 30 x base coverage (average depth of 
~ 36.9 x base coverage). As reference sample, liver biopsies was sequenced to equal depth for 
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the different donors. Sequence reads were mapped against human reference genome GRCh37 
using Burrows-Wheeler Aligner (BWA) 0.7.5a with settings 'bwa mem -c 100 -M' resulting in 
sample-specific BAM files. To predict CNVs, BAM files were analyzing using Control-
FREEC (Boeva et al., Bioinformatics 28, 423-5 (2012)) and DELLY (Rausch et al., 
Bioinformatics 28, i333-i339 (2012)). To obtain somatically acquired CNVs, we filtered 
called CNVs for occurrence in the reference samples (liver biopsies). Single nucleotide 
variants were multi-sampled called using the Genome Analysis Toolkit (GATK) v2.7.2 
UnifiedGenotyper (DePristo et al., Nat Genet 43, 491-8 (2011)). We only considered 
positions at autosomal chromosomes, which were covered at least 20x in all liver stem cell 
samples and corresponding biopsy from the same donor. Candidate somatic SNVs were 
further filtered using the following criteria: no evidence in reference samples; minimal 
alternative allele frequency of 0.3 to exclude sequencing artefacts and potential substitutions 
that occurred after the clonal step; a minimal GATK quality score of 100; no overlap with 
single nucleotide polymorphisms (SNPs) in the Single Nucleotide Polymorphism Database 
(dbSNP 137.b37); and no overlap with SNVs in the other tested individual (Figure S2). 
 
Immunohistochemistry, immunofluorescence and Image analysis 
Tissues and organoids were fixed o/n with formalin or 4% PFA respectively, and stained 
washed and transferred to tissue cassettes and paraffin blocks using standard methods. Tissue 
sections (4 μM) were prepared and stained with antibodies, H&E or PAS using standard 
techniques. The antibodies and dilutions used are listed in Table S5. Stained tissues were 
counterstained with Mayer’s Hematoxylin. Pictures were taken with a Nikon E600 camera 
and a Leica DFDC500 microscope (Leica). For whole mount immunofluorescence staining, 
organoids were processed as described in Barker et al, (Barker et al., 2010). Nuclei were 
stained with Hoechst33342 (Molecular Probes). Immunofluorescence images were acquired 
using a confocal microscope (Leica, SP5). Images were analyzed and processed using Leica 
LAS AF Lite software (Leica SP5 confocal). All phase contrast pictures were acquired using 
a Leica DMIL microscope and a DFC420C camera. 
 
RT-PCR and qPCR analysis 
RNA was extracted from organoid cultures or freshly isolated tissue using the RNeasy Mini 
RNA Extraction Kit (Qiagen), and reverse-transcribed using reverse-transcribed using 
Moloney Murine Leukemia Virus reverse transcriptase (Promega). All targets were amplified 
(40 cycles) using gene-specific primers and MiIQ syber green (Bio-Rad). Data were analysed 
using BioRad CFX manager. For Supplemental Figure S7, cDNA was amplified in a thermal 
cycler (GeneAmp PCR System 9700; Applied Biosystems, London, UK) as previously 
described (Huch et al., 2009). Primers used are listed in Table S4. 
 
Functional hepatocyte studies 
To assess glycogen storage and LDL uptake, liver organoids grown in EM or DM for 11 days 
were stained by Periodic acid-Schiff (PAS, Sigma) and DiI-Ac-LDL (biomedical 
technologies), respectively, following manufacturer’s instructions. To determine albumin and 
A1AT secretion, liver organoids were differentiated as described. Culture medium was 
changed every 3-4 days and culture supernatant was collected was collected 24h after the last 
medium change. HepG2 (ATCC number 77400) and HEK293T (ATCC number CRL-3216) 
cells were cultured for 24h in the same medium without growth factors and were used as 
positive and negative control respectively. The amount of albumin and A1AT in culture 
supernatant was determined using a human specific Albumin or human specific A1AT ELISA 
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kit (both from Assay Pro). To measure Cyp3a activity the cultures were differentiated as 
described and the day of the experiment the cells were removed from the matrigel and 
cultured with the Luciferin-PFBE substrate (50 µM) in Hepatozyme medium supplemented 
with 10% FBS (Gibco). As controls, HepG2 and HEK293Tcells were cultured for 24h in 
DMEM 10%FBS and the day of the experiment transferred to Hepatozyme medium 
supplemented with 10% FBS (Gibco) and Luciferin-PFBE substrate (50 µM). Cytochrome 
P450 activity was measured 8h later using the P450-Glo Assay Kit (Promega) according to 
manufacturer’s instructions.  
Concentrations of midazolam, 1-hydroxymidazolam (1-OH-M) and 1-hydroxymidazolam-
glucuronide (1-OH-MG) were determined in 50 microliter using LC-MS/MS. Analysis was 
carried out at the Clinical Pharmaceutical and Toxicological Laboratory of the Department of 
Clinical Pharmacy of the University Medical Center Utrecht, the Netherlands. All 
experiments were performed on a Thermo Fisher Scientific (Waltham, MA) triple quadrupole 
Quantum Access LC-MS/MS system with a Surveyor MS pump and a Surveyor Plus 
autosampler with an integrated column oven. Analytes were detected via MS/MS, with an 
electrospray ionization-interface in selected reaction monitoring-mode, by their parent and 
product ions. The method showed linearity over the range of 0.02 – 1.50 mg/L for MDZ and 
OHM and over the range of 0.10 – 10.0 mg/L for HMG. The analytical accuracy and 
precision were within the maximum tolerated bias and CV (20% for LLOQ, 15% for the other 
concentrations). Since a 1-OH-MG standard was not available, a Gold Standard was used. 
The Gold Standard consisted of the urine from two adult intensive care patients with a high 
dose of intravenous midazolam and good renal function. Total bile acids were measured on an 
AU5811 routine chemistry analyzer (Beckman Coulter, Brea, California) with an enzymatic 
colorimetric assay (Sentinel Diagnostics, Milano, Italy). Ammonia elimination was analysed 
as follows: organoid cultures were expanded and differentiated in DM medium for 8 days. On 
day 8 CAG was added to the medium and 3 days later the organoids were remouved from the 
matrigel, washed with Williams’ medium and subsequently incubated with 1 mL of test 
medium (Williams’ E medium (Lonza, Basel, Switzerland) with 10% fetal bovine serum 
(Lonza), 5 µg / mL insulin (Sigma, St. Louis, U.S.), 50 µM hydrocortisone hemisuccinate 
(Sigma), 2mM glutamine (Lonza), 50 U / mL penicilline and 50 µg / mL streptomycin 
(penicilline/streptomycine mix (Lonza),  1.5 mM NH4Cl (Sigma), 2.27 mM D-galactose 
(Sigma), 2 mM L-lactate (Sigma) and 2 mM ornithine hydrochloride (Sigma)). Then 0.25 mL 
samples were taken after 45 min, 7 and 24 hrs and stored at -20°C for further analysis. 
Subsequently, all cultures were washed twice with PBS, trypsinized and cell number was 
counted by tripan blue exclusion. 
Concentrations of ammonia were assessed in all samples by using the Ammonia (rapid) kit 
(Megazyme International, Wicklow, Ireland). The rates of ammonia elimination were 
established by calculating the changes in absolute molecular amounts of ammonia in the 
medium and corrected for time and cell number. 
 
SERPINA1 sequencing 
All 4 SERPINA1 exons were amplified from genomic DNA using Phusion High-fidelity 
DNA polymerase (Thermo Scientific) and specific primersets (see Table S4). PCR products 
were purified using QIAquick PCR purification kit (Qiagen) and sequenced on an ABI 
3730XL capillary sequencer. 
 
Enzymatic Elastase inhibition assay 
For measurement of the inhibitory action of α1-antitrypsin in organoid supernatants, donor 
and patient organoids were differentiated for 11 days. Culture medium was changed every 2-3 
days and culture supernatant was collected 24h after the last medium change. For the assay, 
160 ul of supernatant are mixed with 20 ul of a 2 mg/ml N-Succinyl-Ala-Ala-Ala-p-
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nitroanilide (Sigma) 100 mM Tris pH 8.0 solution in a clear-bottom 96-well plate. After 
addition of 6x10-4 U of Elastase (porcine pancreas, Sigma) in 100 mM Tris pH 8.0, the 
increase in absorbance at 410 nm is measured continuously over 30 minutes. Elastase 
inhibition by supernatants is measured as the decreased inclination of absorbance over time in 
comparison to uninhibited controls (plain medium) and compared to a dilution series of 
purified human α1-antitrypsin (Zemaira) in medium. 
  
Detection of eIF2α phosphorylation 
Donor and α1-antitrypsin deficient patient organoids were differentiated for 11 days. Culture 
medium was changed every 2-3 days and organoids were lysed in Lysis buffer (50 mM Tris 
pH 7.5, 50 mM NaCl, 0.5% Triton-X100, 0.5% NP40 substitute, 5 mM EGTA, 5 mM EDTA, 
1x Complete protease inhibitor (Roche), 1x PhosStop (Roche)). Using standard techniques 
lysates were resolved by SDS-Page and blotted on PVDF membranes (Millipore). Antibodies 
against are listed in Table S5. 
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Figure S1: TgFb inhibition, active Wnt signaling and cAMP activation are essential for the long term expan-
sion of human liver cells. Related to Figure 1. 
A-E: Liver tissue was digested using collagenase dissociation as described in Material and Methods. Single cell 
suspensions were counted and 3000 or 10000 cells were seeded per well in a 48well plate. Cells were cultured in 
mouse liver medium containing Egf, Rspo, Fgf10, Hgf and Nicotinamide (ERFHNic) or the same medium supple-
mented with A8301 (+A) or forskolin (+FSK) or the indicated compounds. A: Representative images of organoid 
cultures grown in the mouse medium (ERFHNic) or medium supplemented wiht A8301 (+A). B: Gene expression of 
TGFb target genes, sequesters and inhibitors in 2 weeks old cultures maintained in mouse medium. Results are 
expressed as microarray signal of the specific gene after normalization. C: Gene expression of the specific TGFb 
genes downregulated upon A8301 treatment. Results are expressed as log2 fold change when comparing cutlures 
treated vs non-treated. D: Gene expression of LGR5, KRT19, ALB and CYP3A4  upon FSK treatment. E: Images of 
organoid cultures treated for up to 8 passages with the indicated cAMP activators. F: Expanding human liver organoids 
grown in complete medium as described in Methods were maintained in that medium (complete) or transferred to a 
medium without Rspo (-Rspo), without FSK (-FSK) or both (-Rspo-FSK). After withdrawal the cultures deteriorated and 
could not longer be passaged. Representative image of 1 donor material 7 days after withdrawal. G: Quantification of 
the number of organoids per well after a 7 days withdrawal of Rspo or FSK or both. Results are expressed as the mean 
+/- SEM of 2 independent human donor material and 2 independent experiements.  H: Addition of the porcupine inhibi-
tor  (IWP2) to the medium resulted in growth arrest evident as early as 5 days after the treatment. That effect could be 
rescued by the exogenous addition of Wnt into the medium (+Wnt3a). Representative images taken 12 days after treat-
ment. Organoid numbers were counted 12 days after the treatment. Graph indicating the number of organoids in the 
presence/absence of the indicated compounds. Results are expressed as mean +/- SEM of 2 independent human liver 
cultures.
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Figure S2: Human liver cultures are of ductal origin. Related to Figure 1.
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(A) Cyp3A4 activity of Percoll purified primary human hepatocytes after 4 days in culture in comparison to 
HepG2 cells. (B) EpCAM marks bileducts in human liver sections. Hepatocytes are EpCAM negative. (C) 
sorting strategy to purify EpCAM+ ductal cells and Hepatocytes. In the first step, singlets were gated to 
avoid contamination by cell aggregates. Subsequently, large debris and erythrocytes were excluded. 
From this population, EpCAM+ PI- (viable) cells were sorted as the ductal population. For hepatocyte sort-
ing large EpCAM- cells were selected. (D) Organoid formation efficiency of sorted ductal and hepatocyte 
populations after 14 days. Organoids bigger than 100 µm were scored. (E) EpCAM+ sort derived orga-
noids at passage 0 and passage 6. (F-G) Organoid formation efficiency of unsorted, Percoll purified 
hepatocytes (F) and the respective percentage of residual EpCAM+ cells (G). 
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Figure S3: Filtering steps and FNR of all sequenced samples. Related to Figure 2
A: Total number of base substitutions after various filtering steps:
(1) Multi-sample called (biopsy, 2 parental cultures, 2 subclonal cultures for both donors) base substituions with UnifiedGenotyper from GenomeAnalysis 
toolkit version 2.8-1.
(2) First quality control was performed with VariantFiltration from GenomeAnalysis toolkit version 2.8-1 with settings:
--clusterWindowSize 10
--filterExpression "MQ0 >= 4 && ((MQ0 / (1.0 * DP)) > 0.1)" --filterName "HARD_TO_VALIDATE" 
--filterExpression "QUAL < 100.0 " --filterName "LowQual" 
--filterExpression "QD < 1.5 " --filterName "LowQD" 
(3) Base substitutions with a coverage of at least 20X in all samples.
(4) Base substitutions at autosomal chromosomes.
(5) Base substitutions without any evidence in the biopsy sample (somatic events).
(6) Base substitutions were called if PNR >= 0.3 in the subclones. Base substitutions that were called and also have evidence in the other subclone of the 
same individual are removed if the 0 < PNR < 0.3 and the number of alternative reads is >1.
(7) Base substitutions without a dbSNP_137 identifier.
(8) Base substitutions without evidence in the other individual.
B: Estimation of False Negative Rate (FNR). The germline SNP sets consist of base substitutions that pass filter steps 1-4, are called in the biopsy of the 
donor with a PNR >= 0.3 and number of alternative alleles > 1. Subsequently, base substitutions were called in the subclonal cultures that passed filter 
steps 1-4 and 6. Germline SNPs that were missed in the subclonal cultures are used to calculate the FNR. 
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Figure S4:  Genetic stability of human liver stem cell cultures. Related to Figure 3
A:Chromosome numbers were counted on a total of 76 metaphases from 2 different donors. B-D: Genetic stability was evaluated on 
clonally expanded cultures from 1 donor by WGS. Absence of DNA-Copy number alterations in human liver stem cell cultures clonally 
expanded long-term in culture. Box plots display the Log2 intensity ratios for the original biospy (B), clone 3 (C) or subclone of the clone 
3 (D) for chromosomes 1 to 22. 
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Figure S5: Analysis of organoids during expansion and upon differentiation. Related to Figure 5 and 6
(A) Representative image of RT-PCR analysis of indicated genes in 2 independent human liver donor-derived 
organoid cultures maintained in Expansion medium (EM) for 2 months in culture. Note expression of progenitor 
marker PROM1 and ductal marker OC2 (ONECUT2). (B) Heat map of genes >2 fold differentally expressed 
between human liver tissue and organoid in expansion medium. Red, upregulated. Green, downregulated, 
Black, not differentially expressed. (C) Representative image of RT-PCR analysis of indicated genes in 1 donor 
derived culture maintained under complete expansion medium (EM) or after withdrawal of Rspondin (Rspo) or 
Forskolin (FSK). (D)  Representative image of RT-PCR analysis of CYP3A4 in 1 donor derived culture main-
tained under complete differentiation medium (DM, complete) for 11 days, or after withdrawal of the indicated 
components, DAPT and/or Dexamethasone (Dexa). (E) Representative image of RT-PCR analysis of indicated 
genes in 2 independent human liver donor derived organoid cultures maintained in Expansion medium (EM) for 
2 months in culture or after 11 days in Differentiation medium (DM). Note expression of hepatocyte markers 
TAT and cytochromes exclusively upon differentiation. (A-E) + control, human liver lysate (F-G) EpCAM+ cell 
derived organoids were differentiated for 11 days according to our differentiation protocol. (F) Immunofluores-
cent Albumin and Krt19 staining show presence of differentiated cells of biliary and hepatocyte lineage. (G) 
qRT-PCR for differentiation markers of the hepatocyte (Alb and Cyp3A) and ductal (Krt19 and Krt7) lineage 
show successful differentiation of EpCAM+ cell derived organoids to hepatocytes.
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Figure S6: Transplantation of human liver organoids into damaged mouse liver. Related to 
Figure 6.
(A) Control staining for human specific Albumin (hAlbumin) and Kertatin-19 (hKrt19) antibodies. hAlbu-
min recognises human but not mouse hepatocytes, whereas hKrt19 stains human but not mouse bile 
ducts. (B) Liver sections of mice sacrificed 2 hours or 2 days after human liver organoid cell transplan-
tation stained for hKrt19. After 2 hours human cells are mostly seen in blood vessels in and around 
portal veins, whereas cells start to engraft in the tissue 2 days after the transplant. (C) Example singlet 
or doublet human Albumin positive hepatocytes observed in the liver of human liver organoid trans-
planted Balbc/nude mice. (D) Human serum Albumin levels of individual transplanted mice over 120 
days. (E) Average human serum alpha-1-antitrypsin levels of transplanted mice over 120 days. Results 
are shown as ± SEM of 2 vehicle control animals and 3 human liver organoid transplanted animals.
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Figure S7: Organoids from A1AT-Deficiency and AGS patients mimic disease phenotypes in vitro. 
Related to Figure 7. 
(A) SERPIN1A Sanger Sequencing of Donor #1 and α1AT Patient #1. Chromatograms of 3 A1AT-deficient 
patients (PiZZ) and 1 donor with wildtype SERPINA1 (PiMM). The homozygous G to A mutation causes an 
amino acid change from glutamic acid to lysine at position 342. (B)  Clustering analysis of the different 
donors (1-5) and α1AT Patient (A1AT_pat) organoids and tissues. Note that, regarding differentiation ability, 
the behaviour of α1AT Patient derived organoids resembles donor derived organoids. i.e. organoids in EM 
cluster cluster with donor EM organoids and α1AT-D organoids cultured in DM cluster with donor derived 
organoids cultured in DM conditions.  (C) histological staining for cleaved caspase-3 in donor and α1AT 
Patient derived organoids differentiated in DM for 11 days. (D) quantification of apoptotic cells in wildtype 
and α1AT Patient derived organoids in EM and after differentiation in DM. Results are shown as ± SEM of 
6 random sections of organoids per 2 independent donors and patients. (E) qRT-PCR of Lgr5 and ductal 
markers (Krt19 and Krt7) in EM and after ductal differentiation. AGS patients fail to upregulate ductal mark-
ers upon differentiation. (F) Immunofluorescence of differentiated wildtype and AGS patient organoids. 
Krt19 positive cells in AGS patient organoids do not integrate into the epithelium and show signs of apopto-
sis (arrows).  EM, expansion medium. DM, differentiation medium, ductal diff, ductal differentiation medium 
(see text). AGS, Alagille syndrome.
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Table	  S1:	  Summary	  of	  compounds	  tested	  on	  top	  of	  the	  mouse	  liver	  medium
Compound	  	   Effect* Function Concentration	  used/tested Source
A8301 	  +	  keep	  for	  long	  term Alk4/5/7	  inhibitor 0,5µM	  -­‐	  5µM Tocris	  2939
Nicotinamide 	  +	  keep	  for	  long	  term PARP-­‐1	  inhibitor 10mM Sigma	  N0636
AA	  (arachindonic	  acid) 	  +	  after	  initiation endogenous	  free	  fatty	  acid	  (precursor	  of	  PGE) 10µg/ml Tocris	  2756
PGE2	  (prostaglandin	  E2) +	  after	  initiation	  but	  makes	  cystic	  culture endogenous	  prostaglandin 10nM Tocris	  2296
Y-­‐27632	   +	  after	  initiation p160ROCK	  inhibitor 10µM Sigma	  Y-­‐27632
hES	  Cell	  Cloning	  &	  Recovery	  Supplement +	  after	  initiation contains	  thiazovivin 2µM Stemgent	  01-­‐0014-­‐500
CHIR99021 + GSK3b	  inhibitor 0,5µM StemGent	  Chir99021
Wnt3a + Wnt	  agonist 30% Conditioned	  Medium
BMP7 	  +	  for	  differentiation BMP	  agonist,	  Alk 25ng/ml Peprotech	  120-­‐03
NKH	  477	  (forskolin	  analog) 	  + Adenyl	  cyclase	  activator	  (cAMPactivator) 10µM Tocris	  1603
8-­‐bromo-­‐cAMP	   	  + cAMP	  analog 10µM Tocris	  1140
Cholera	  toxin 	  + cAMP. 100ng/ml Sigma	  8052
Forskolin 	  +	   Adenyl	  cyclase	  activator	  (cAMPactivator) 10µM Tocris	  1099
FGF19 	  +	  for	  differentiation FGF	  signaling 100ng/ml R&D	  969-­‐FG
Jagged	  1 	  +	  mild Notch	  ligand	   1µM anaspec	  61298
Thiazovivin	   	  	  +	  after	  passage	  keep	  adding	  after	  passage Rock	  inhibitor	   2µM Tocris	  3845
SB202190 	  +	  mild p38	  inh 300nM	  /	  3µM Sigma	  SB	  202190
SB431542	   	  +	  mild Alk5	  inh 10µM Tocris	  1614
IGF 0/+	  mild Igfr	  ligand 100ng/ml Peprotech	  250-­‐19
Valproic	  acid 0/+	  mild HDAC	  inhibitor 1mM StemGent	  04-­‐0007
Byk204165 0 PARP-­‐1	  inhibitor 10µM Tocris	  3734
DR2313 0 PARP-­‐1	  PARP-­‐2	  inhibitor 40µM Tocris	  2496
Oncostatin	  M 0/+ Cytokine 100ng/ml R&D	  295-­‐OM
Ciglitazone 0/+ PARP-­‐gamma	  agonist 3µM Tocris	  1307
Dorsomorphin 0/+ ALK2,	  ALK3	  and	  ALK6	  inhibitor.	  AMPK	  inhibitor 1µM Tocris	  3093
Pyrintegrin 0/+ unknown,	  facilitates	  reprograming(1) 10µM Stemgent	  04-­‐0072
h	  noggin	  recombinant	   0/+ BMP	  inhibitor/sequesters	  BMP 25ng/ml Peprotech	  120-­‐10C
ID8 0/+ unknown,	  estimulates	  ESC	  proliferation(2) 10µM Tocris	  3853
Ascorbic	  acid	   0/+ antioxidant 50µM sigma	  5960
Antioxidant	  supplement 0/+ antioxidant 1x sigma	  A1345
Follistatin	   0/+ Activin-­‐binding	  molecule,	   100ng/ml Peprotech	  120-­‐13
FGF2 	  0/-­‐ FGF	  singaling 10ng/ml R&D	  	  233-­‐FB
DAGKi 	  -­‐ Diacylglycerol	  kinase	  inhibitor	   10µM Sigma	  D5919
Human	  sRANK	  Ligand -­‐ Tnf	  family	  member,	  cytokine 100ng/ml Peprotech	  310-­‐01
Zardaverine -­‐ PDE	  III/IV	  inhibitor. 10µM Tocris	  1046
Retinoic	  Acid 	  -­‐ Retinoic	  acid	  signaling 10µM Tocris	  302-­‐79-­‐4
FBS 	  -­‐ fetal	  bovine	  serum 5-­‐50% Gibco
human	  serum 	  -­‐ human	  serum 5-­‐50% donated	  from	  WKZ#
IWP2 	  -­‐ Porcupine	  inhibitor 3uM Tocris	  3533
* #WKZ=	  Whilhelmina	  KinderZiekenhuis	  (Utrecht)
positive	  effect	  to	  expand	  the	  cultures	  
mild	  positive	  effect
no	  effect,	  either	  positive	  or	  negative
negative	  effect
(1)Xu,	  Y.,	  et	  al.	  (2010)	  Revealing	  a	  core	  signaling	  regulatory	  mechanism	  for	  pluripotent	  stem	  cell	  survival	  and	  self-­‐renewal	  by	  small	  molecules.	  Proc	  Natl	  Acad	  Sci	  USA	  107:	  8129-­‐8134.
(2)Miyabayashi	  et	  al	  (2008)	  Indole	  derivatives	  sustain	  embryonic	  stem	  cell	  self-­‐renewal	  in	  long-­‐term	  culture.	  Biosci.Biotechnol.Biochem.	  72	  1242.	  PMID:	  18460821.
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Table	  S2:	  Donor	  and	  A1AT-­‐patient	  material
material gender age associated	  pathology A1AT	  levels
1 M 55 donor
2 M 74 donor
3 F 49 donor
4 M 14 donor
5 M 65 donor
6 F 51 donor
7 F 72 donor
8 M 53 donor
9 M 30 donor
10 M 34 donor
11 M 77 donor
12 M 43 donor
patient	  1 F 55 AAT-­‐1 0.20	  g/L
patient	  2 M 64 AAT1 0.27	  g/L
patient	  3 M 42 AAT1 0.18	  g/L
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Table	  S3:	  List	  of	  base	  substitutions	  found	  in	  coding	  regions
DONOR CULTURE CHROMPOS MUTATION EFFECT GENOTYPE ENSEMBL_ID GENE	  SYMBOL ALTERNATIVE	  ALLELE	  FREQUENCY	  EARLY	  PASSAGE ALTERNATIVE	  ALLELE	  FREQUENCY	  LATE	  PASSAGE
1 A 1 32207238 G>A SYNONYMOUS_CODING Heterozygous ENSG00000121753 BAI2 0.089552239 0.688888889
1 A 1 75622602 C>T NON_SYNONYMOUS_CODING Heterozygous ENSG00000162624 LHX8 0.545454545 0.628571429
1 A 2 207424806 G>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000114948 ADAM23 0.418181818 0.641025641
1 A 3 179076677 G>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000171109 MFN1 0.512820513 0.5
1 A 10 5496434 T>A SYNONYMOUS_CODING Heterozygous ENSG00000173848 NET1 0.575757576 0.583333333
1 A 11 76234307 A>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000158636 C11orf30 0.523809524 0.431818182
1 A 12 91449659 C>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000139330 KERA 0.454545455 0.68
1 A 17 39780577 C>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000128422 KRT17 0.583333333 0.351351351
1 A 19 44351529 G>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000167637 ZNF283 0.452380952 0.428571429
1 B 3 134362202 T>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000174611 KY 0.528301887 0.484848485
1 B 4 139981771 C>T SYNONYMOUS_CODING Heterozygous ENSG00000109381 ELF2 0.575757576 0.607142857
1 B 6 82459603 G>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000112773 FAM46A 0.425 0.4
1 B 7 149558467 A>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000106479 ZNF862 0.536585366 0.588235294
1 B 12 32480802 G>T NON_SYNONYMOUS_CODING Heterozygous ENSG00000151746 BICD1 0.578947368 0.42
1 B 18 44626712 G>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000167216 KATNAL2 0.525 0.5
1 B 22 32109952 C>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000183530 PRR14L 0.441176471 0.5
2 A 4 56883895 C>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000174799 CEP135 0.083333333 0.382352941
2 A 5 147443636 T>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000133710 SPINK5 0.466666667 0.488372093
2 A 6 152650892 G>A SYNONYMOUS_CODING Heterozygous ENSG00000131018 SYNE1 0 0.481481481
2 A 11 46394008 T>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000149091 DGKZ 0.454545455 0.558139535
2 A 12 110834179 C>T SYNONYMOUS_CODING Heterozygous ENSG00000196510 ANAPC7 0.525 0.548387097
2 A 15 42021381 A>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000174197 MGA 0.448275862 0.425531915
2 A 15 55475578 A>T NON_SYNONYMOUS_CODING Heterozygous ENSG00000137876 RSL24D1 0.303030303 0.709677419
2 A 18 22057361 A>G SYNONYMOUS_CODING Heterozygous ENSG00000134489 HRH4 0.428571429 0.545454545
2 B 2 39089367 C>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000163214 DHX57 0.37037037 0.631578947
2 B 2 55252862 C>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000115310 RTN4 0.742857143 0.428571429
2 B 2 63486493 C>A NON_SYNONYMOUS_CODING Heterozygous ENSG00000143951 WDPCP 0.590909091 0.651162791
2 B 2 203072632 A>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000116030 SUMO1 0.32 0.555555556
2 B 3 3216846 C>A ESSENTIAL_SPLICE_SITE Heterozygous ENSG00000113851 CRBN 0.428571429 0.514285714
2 B 4 2948189 C>T NON_SYNONYMOUS_CODING Heterozygous ENSG00000087269 NOP14 0.472222222 0.5
2 B 7 111585853 A>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000128512 DOCK4 0.53125 0.3
2 B 8 25225715 G>C NON_SYNONYMOUS_CODING Heterozygous ENSG00000147459 DOCK5 0.487804878 0.484848485
2 B 13 50050713 C>G NON_SYNONYMOUS_CODING Heterozygous ENSG00000136169 SETDB2 0.541666667 0.428571429
Base	  substitution	  accumulated	  during	  long-­‐term	  culturing,	  without	  evidence	  in	  the	  early	  passage
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Table	  S4:	  List	  of	  primers	  
Primers	  used	  for	  gene	  expression	  analysis
Official	  Gene	  Symbol Official	  name	   RefSeq	  Accession	  number	   forward	  5'-­‐3' reverse	  5'-­‐3' PCR	  product	  (bp) used	  for
ALB Homo	  sapiens	  albumin	  (ALB),	   NM_000477.5 CTGCCTGCCTGTTGCCAAAGC	  	   GGCAAGGTCCGCCCTGTCATC	  	   260 qPCR	  and	  RT-­‐PCR
AXIN2 Homo	  sapiens	  axin	  2	  (AXIN2) >NM_004655.3	   AGCTTACATGAGTAATGGGG AATTCCATCTACACTGCTGTC 346 qPCR
BACTIN Homo	  sapiens	  actin,	  beta-­‐like	  2	  (ACTBL2) >NM_001017992.3	   AGTATCCTATCGAGCATGGA CATCTTTTCCCGGTTGATCT 155 qPCR
CYP1A1 Homo	  sapiens	  cytochrome	  P450,	  family	  1,	  subfamily	  A,	  polypeptide	  1	  (CYP1A1) NM_000499.3 GTGATCCCAGGCTCCAAGAGTCCA 	  AAATCATCGCCCTGCCGCACC 386 RT-­‐PCR
CYP2B6 Homo	  sapiens	  cytochrome	  P450,	  family	  2,	  subfamily	  B,	  polypeptide	  6	  (CYP2B6)	   >NM_000767.4	   TGGCCGGGGAAAAATCGCCA GAAGAGCTCAAACAGCTGGCCGAA 373 RT-­‐PCR
CYP3A4 Homo	  sapiens	  cytochrome	  P450,	  family	  3,	  subfamily	  A,	  polypeptide	  4	  (CYP3A4) NM_017460.5 TGTGCCTGAGAACACCAGAG GTGGTGGAAATAGTCCCGTG 226 qPCR	  and	  RT-­‐PCR
GAPDH Homo	  sapiens	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  (GAPDH) >NM_002046.4	   AGAAGGCTGGGGCTCATTTG AGGGGCCATCCACAGTCTTC 258 RT-­‐PCR
GAPDH Homo	  sapiens	  glyceraldehyde-­‐3-­‐phosphate	  dehydrogenase	  (GAPDH) >NM_002046.4	   GCATCTTCTTTTGCGTCG TGTAAACCATGTAGTTGAGGT 181 qPCR
HNF4A Homo	  sapiens	  hepatocyte	  nuclear	  factor	  4,	  alpha	  (HNF4A)	   NM_178850.1 CGTGCTGCTCCTAGGCAATGAC ACGGACCTCCCAGCAGCATCT 413 RT-­‐PCR 	  
HNF4A Homo	  sapiens	  hepatocyte	  nuclear	  factor	  4,	  alpha	  (HNF4A) NM_178850.1 GTACTCCTGCAGATTTAGCC CTGTCCTCATAGCTTGACCT 162 qPCR
HPRT1 Homo	  sapiens	  hypoxanthine	  phosphoribosyltransferase	  1	  (HPRT1) >NM_000194.2	   AAGAGCTATTGTAATGACCAGT CAAAGTCTGCATTGTTTTGC 132 qPCR
KRT	  19 Homo	  sapiens	  keratin	  19	  (KRT19) NM_002276.4 CGCGGCGTATCCGTGTCCTC	   AGCCTGTTCCGTCTCAAACTTGGT	   396 qPCR	  and	  RT-­‐PCR 	  
KRT7 Homo	  sapiens	  keratin	  7	  (KRT7) >NM_005556.3	   CTCCGGAATACCCGGAATGAG ATCACAGAGATATTCACGGCTCC 347 RT-­‐PCR
LGR5 Homo	  sapiens	  leucine-­‐rich	  repeat	  containing	  G	  protein-­‐coupled	  receptor	  5	  (LGR5)	   NM_001277226.1 GACTTTAACTGGAGCACAGA AGCTTTATTAGGGATGGCAA 282 qPCR	  and	  RT-­‐PCR
ONECUT2 Homo	  sapiens	  one	  cut	  homeobox	  2	  (ONECUT2) NM_004852.2 CCCAACTTCGACGCGCACCA	  	   TCTTTGCGTTTGCACGCTGCC	  	   467 RT-­‐PCR
PROM1 Homo	  sapiens	  Prominin	  1	  (PROM1,	  alias	  CD133) NM_006017.2 	  ACACTGAAAGTTACATCCACAGAA GGGTGTATCCAAAACCCGGA 350 RT-­‐PCR
RNF43 Homo	  sapiens	  ring	  finger	  protein	  43	  (RNF43) >NM_017763.4	   AAATTAATGCAGTCCCACCC AAACTCCATCAGCTTCTCAG 285 qPCR
SOX9 Homo	  sapiens	  SRY	  (sex	  determining	  region	  Y)-­‐box	  9	  (SOX9) NM_000346.3 GGAAGTCGGTGAAGAACGGG 	  	  TGTTGGAGATGACGTCGCTG 321 qPCR	  and	  RT-­‐PCR
TAT Homo	  sapiens	  tyrosine	  aminotransferase	  (TAT)	   NM_000353.2 TGTCGCACCCCGGGAGAGTT	  	   CAAAGCACGTTGCTGGGAGGCA 238 RT-­‐PCR
Primers	  used	  for	  gene	  sequencing	  analysis
Official	  gene	  symbol Official	  name	   RefSeq	  Gene forward	  5'-­‐3' reverse	  5'-­‐3' PCR	  Product	  (bp) use Exon mutation
SERPINA1 Homo	  sapiens	  Serpin	  peptidase	  inhibitor,	  clade	  A	  (alpha-­‐1	  antiproteinase,	  antitrypsin),	  member	  1 NG_008290.1 ACATGTGAGCACGGAGAACA TTCTGGGACACTAGAGTCGTG 1228 Amplification
ATCATGTGCCTTGACTCGGG 	  -­‐ 	  -­‐	   Sequencing
AGGGAGGGGACTCATGGTTT TGCCCAGTGACAACCGTTTA 1266 Amplification
TCCAAACCTTCACTCACCCC 	  -­‐ 	  -­‐	   Sequencing
AAACCAAAGCCGAGTTCCCA TTCTCGTCGATGGTCAGCAC 1158 Amplification
GTGGTGGGTCCCAGAAGAAC 	  -­‐ 	  -­‐	   Sequencing
TCAGCCAAAGCCTTGAGGAG GGTGATGTGCTTCCTCTCCC 1296 Amplification
TGGGATCAGCCTTACAACGTG 	  -­‐ 	  -­‐	   Sequencing
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Table S5: List of Antibodies 
Primary antibodies
antigen raised Source and cat number dilution Application  fixation method & details
human Ecad mouse BD Biosciences (BD Transduction Laboratories™) 610182 (mouse and human) 1:500 IF PFA 4%
human EpCAM mouse eBioscience, Anti-Human CD326 (EpCAM) Alexa Fluor® 488  1:100 IHC-P and FlowCytometry Formalin + Tris-EDTA antigen retrieval
Albumin goat Santa Cruz  ALB -N18  -sc46291 1:50 in pbs 0.1%BSA IF PFA 4%
human Albumin goat Bethyl Laboratories, Human Albumin cross-adsorbed Antibody (HRP conjugated)  1:50/1:200 IHC-P/IF Formalin + Tris-EDTA antigen retrieval
cleaved Caspase-3 rabbit Cell signaling, cleaved Caspase-3 #9661  1:500 IHC-P/IF Formalin + Tris-EDTA antigen retrieval
K19 mouse Cell Signaling  #4558 -BA17 1:100 in PBS1%FBS IHC-P/IF Formalin + Tris-EDTA antigen retrieval
Krt7 mouse Millipore- MAB3226 1:200 IF PFA 4%
HNF4a rabbit Santa Cruz   Hnf4a-(H-171) -sc8987 1:50 (not concentrated) in PBS0.1%BSA IF PFA 4%
ZO1 rabbit Invitrogen ZO-1 - 40-2200 1:200 o/n 4c in PBS1% FBS IF Acetone fix
Mrp4 rat Abcam Anti-MRP4 antibody [M4I-10] (ab15602) 1:20 - 1:50 in PBSO 0.03%BSA OR  PBSO+1%FBS IF Acetone fix
EpHB2 rat IgG2A R&D Systems EphB2 Mab (clone 512012)- MAB467  1:100, IF PFA
Lgr5 rabbit Abgent LGR5/GPR49 Antibody (loop2) ID: RB14211     cat n: AP2745d  LOT:SH080411H  1:100 IF and FlowCytometry PFA
AAT1a rabbit Abcam Anti-alpha 1 Antitrypsin antibody - ab9373 1:500-1:1000 IHC-P Formalin + citrate antigen retrieval 
Phospho-eIF2alpha (Ser51) rabbit  Cell Signaling # 9721 1:1000 western blot N/A
eIF2α Antibody rabbit Cell Signaling #9722 1:1000 western blot N/A
GAPDH rabbit Abcam-Anti-GAPDH antibody - Loading Control (ab9485) 1:2500 western blot N/A
Secondary antibodies
antigen raised Source and cat number dilution Application 
Anti-goat Alexa 488 donkey Life Technologies- A11055 (Molecular Probes)  1:250-1:300 IF 
Anti-rabbit Alexa 647 donkey Life Technologies-A31573 (Molecular Probes)  1:250-1:300 IF 
Anti-mouse Alexa 488 donkey Life Technologies-A21202 (Molecular Probes)  1:250-1:300 IF 
Anti-rat Alexa 488 donkey Life Technologies-A-21208 (Molecular Probes)  1:250-1:300 IF 
Anti mouse HRP Dako EnVision+ System- HRP Labelled Polymer Anti-mouse  1:1-1:4 IHC-P
Anti rabbit HRP Dako EnVision+ System- HRP Labelled Polymer Anti-Rabbit  1:1-1:3 IHC-P
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